[{"text": "Angelini Ventures co-leads \u20ac35 million oversubscribed Series B financing in Nobi, an AgeTech company, to expand AI-enabled technology across senior care facilities globally Angelini Ventures Tue, Jan 28, 2025, 9:05 AM 5 min read Angelini Ventures Angelini Ventures\u2019 investment in Nobi demonstrates its continued strategic focus on digital health and connected health devices and represents a significant opportunity to improve the wellbeing of an ageing and vulnerable population. Nobi\u2019s smart lights demonstrate a remarkable 51% reduction in falls and enable 94% faster caregiver response times. By transforming fall detection through AI-powered sensors, Nobi addresses critical challenges in caring for ageing and vulnerable populations, virtually eliminating long-lie periods that can increase mortality risk. Rome, Italy, 28 January 2025 \u2013 Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces that it has co-led an oversubscribed \u20ac35 million Series B financing round in Nobi, an AgeTech company tackling global ageing challenges. Nobi was founded in 2018 by Roeland Pelgrims, with the mission to empower people to age with dignity, safety and happiness. Nobi is looking to revolutionize elderly care by delivering innovative solutions in fall detection, fall prevention, and smart care, transforming the landscape of care homes with its advanced technology, an AI-powered smart light. Falls in care homes represent the biggest cause of hospitalization for elderly residents. The financing round was co-led by Angelini Ventures and Nexus NeuroTech Ventures, in the round also participated 15th Rock, and existing investors EQT Health Economics and EQT Dementia Fund, PMV, and Nobi\u2019s founders Roeland Pelgrims and Bert De Haes as well as Balz Halter. The proceeds of the Series B financing will enable Nobi to strengthen its market leadership position in UK and US and enhance the platform with new features to improve care home workflows. Angelini Ventures selected Nobi as part of its investment strategy to support and advance the most promising healthcare technology companies, from wearable devices to AI-enabled products and solutions, that are transforming industry standards. As the global population ages at an unprecedented rate around the world, healthcare systems are facing increasing pressure to adapt to the needs of older generations creating urgent demand for innovative solutions. Nobi\u2019s AI Smart light is designed to address the challenges of an ageing population, specifically focusing on fall detection and prevention in elderly individuals. Nobi\u2019s innovative light offers a solution to enable seniors to stay at home longer and support them in professional care environments. The lights work in real-time, processing data locally to ensure better privacy and reliability. The AI model was trained for six years by the world\u2019s best AI experts on more than 250,000 real-life situations. Story Continues For fall detection, the lamp uses AI-powered sensors and cameras to monitor the environment continuously. Rapid intervention after a fall is critical, as long-lie periods\u2014when individuals remain on the floor for over an hour\u2014significantly increase the risk of complications or death. Studies show that waiting over an hour raises the likelihood of mortality within six months to 50%. A recent analysis 1 highlights Nobi\u2019s impact. The smart lights enable caregivers to respond 94% faster: reducing waiting times from one hour and eight minutes to just four minutes. Before Nobi, 44% of falls involved long-lie periods over an hour. With Nobi, these incidents were eliminated, ensuring residents receive timely care and relieving caregivers of the stress of finding residents waiting for hours. Recent analysis highlights the significant impact of Nobi's fall prevention technology in care homes. The data reveals that Nobi reduces falls by 51% immediately after installation. At Hartland House, a care home in the UK, fall rates were reduced by 84% following the activation of \u00a0additional prevention measures in a second phase. The success of preventing 4 out of 5 falls at Hartland House has prompted the regional government to expand Nobi\u2019s implementation across 50 additional care homes in Lancashire and South Cumbria. Tanja Dowe, Managing Director of Angelini Ventures , said: \u201c Nobi's technology stands out by seamlessly integrating AI and advanced monitoring capabilities with a deep understanding of elderly care needs. Nobi delivers meaningful, clinically validated improvements to daily care operations in assisted living facilities and care homes, supporting both residents and caregivers. We also appreciate the ability to harness the Nobi platform beyond fall management, extending its use to more expansive health and disease monitoring, as well as care management . \u201d \u201cThis funding milestone is yet another proof of the overwhelming need for AgeTech solutions that combine gold standard technology with award-winning design,\u201d added Roeland Pelgrims, CEO and Co-founder of Nobi . \u201cHaving such a diverse group of world-class investors and an all-star board reaffirms the global potential of our mission.\u201d *** Notes to Editors About Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest \u20ac300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around \u20ac100 million into 18 companies covering a range of therapeutic areas and modalities, including Neumirna, Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience and Freya Biosciences. www.angeliniventures.com About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. www.angeliniindustries.com About Nobu Smart Lights Founded in Belgium in 2018, Nobi is an AgeTech company dedicated to helping people age with dignity, safety, and happiness. Nobi\u2019s flagship product, its award-winning AI-powered smart light, delivers innovative solutions for fall detection, fall prevention, and smart care. Currently employing 50 full-time equivalents (FTEs), Nobi plans to expand its team to 80 FTEs by the end of 2025. With offices in Belgium, the US, and the UK, Nobi\u2019s solutions are available in over 22 countries. Nobi website Contacts Angelini Ventures Paolo Di Giorgio, CEO Martina Palmese, Communications Coordinator martina.palmese@angeliniventures.com Media contacts for Italy - SEC Newgate Italia Daniele Pinosa, daniele.pinosa@secnewgate.it ; Tel. +39 3357233872 Fausta Tagliarini; fausta.tagliarini@secnewgate.it ; Tel. +39 3476474513 Daniele Murgia; daniele.murgia@secnewgate.it ; Tel. +39 3384330031 Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallow angeliniventures@medistrava.com 1 Nobi impact analysis: conducted in five care homes across 2,817 resident days View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-28T06:05:00+00:00", "sentiment": {"score": 0.8681007595732808, "confidence": 0.876549243927002, "probabilities": {"positive": 0.876549243927002, "negative": 0.008448484353721142, "neutral": 0.1150023341178894}}, "embedding": [-0.06840014457702637, -0.056199438869953156, -0.025774579495191574, -0.07241590321063995, 0.05462762713432312, -0.045141272246837616, -0.0223822221159935, 0.016712255775928497, 0.004133207723498344, -0.05212710425257683, 0.09881243854761124, 0.0522567480802536, 0.07763161510229111, 0.01015427615493536, -0.027336962521076202, 0.04657459631562233, -0.02140234224498272, -0.06941394507884979, -0.12417931854724884, 0.10207262635231018, 0.035208091139793396, -0.013049394823610783, 0.015687337145209312, -0.007282746955752373, -0.11466321349143982, 0.008383981883525848, -0.047112345695495605, -0.13329635560512543, -0.11840029060840607, -0.1259574294090271, 0.18310794234275818, 0.2706317901611328, 0.10714232176542282, 0.030954083427786827, -0.13876789808273315, -0.008491460233926773, -0.07237126678228378, 0.023924456909298897, -0.20921531319618225, -0.11361086368560791, -0.039806097745895386, -0.16171970963478088, -0.07253424823284149, -0.053055986762046814, 0.177363783121109, 0.04684992879629135, -0.07464846223592758, -0.12226991355419159, 0.1226988360285759, 0.002934944350272417, -0.24660241603851318, -0.2287800908088684, 0.11622893065214157, 0.08727261424064636, -0.15818747878074646, 0.055205088108778, -0.05283781886100769, -0.09935182332992554, -0.02237609028816223, -0.05024200305342674, 0.1859762966632843, 0.02071932516992092, 0.1540689468383789, 0.006441718898713589, 0.012935418635606766, 0.12148044258356094, 0.012881765142083168, -0.03542373701930046, -0.12227018177509308, -0.18351906538009644, 0.1376635730266571, -0.19837364554405212, 0.023542039096355438, 0.14713209867477417, -0.11641314625740051, 0.10455428063869476, 0.07899264991283417, 0.05498176068067551, 0.09263352304697037, -0.13600493967533112, 0.1270325779914856, 0.005404497962445021, -0.0038610585033893585, 0.1688137650489807, -0.09629511088132858, 0.09790141880512238, 0.06534498184919357, 0.12012501060962677, 0.07324714958667755, -0.06309781968593597, -0.06974416971206665, 0.015825321897864342, -0.012228358536958694, 0.039331816136837006, 0.19298146665096283, -0.14042623341083527, -0.09925755113363266, -0.008266991935670376, -0.0942954421043396, 0.08322890102863312, -0.03854905068874359, 0.00041022885125130415, 0.058448903262615204, 0.07450802624225616, -0.08817996829748154, -0.11193062365055084, 0.08181332051753998, 0.07617401331663132, 0.2461245059967041, 0.11686453223228455, -0.09201963990926743, -0.005134815350174904, 0.02550877071917057, -0.10159602761268616, -0.09742103517055511, -0.011823250912129879, -0.08247222751379013, 0.14542636275291443, 0.22328734397888184, 0.0352107435464859, 0.18242770433425903, 0.07877398282289505, -0.07247412204742432, -0.03028467856347561, 0.15273520350456238, 0.09292764961719513, -0.12206578254699707, 1.1597021719661655e-32, -0.06396590173244476, 0.1718284785747528, -0.06705550104379654, 0.022068869322538376, -0.14609843492507935, -0.08759549260139465, -0.03092040866613388, 0.07065697014331818, -0.17839065194129944, -0.0958154946565628, -0.09210765361785889, 0.09573568403720856, -0.030776817351579666, 0.02447384223341942, 0.08139300346374512, -0.14460954070091248, -0.03264343738555908, -0.0731932520866394, 0.11420013755559921, -0.05751411244273186, -0.09212788939476013, -0.1496623158454895, -0.12969368696212769, 0.08963373303413391, 0.060123153030872345, -0.01108644437044859, 0.03593526408076286, 0.07242919504642487, 0.09357662498950958, -0.0010651769116520882, -0.01920013129711151, 0.09538082778453827, 0.09337081015110016, -0.13189217448234558, -0.04061625152826309, -0.08185628056526184, -0.14741960167884827, -0.0653616264462471, -0.07100071012973785, 0.052319228649139404, -0.1186559647321701, 0.08230996876955032, -0.08570355176925659, -0.019650783389806747, 0.04256153106689453, 0.04489051550626755, 0.09281638264656067, -0.005495170131325722, 0.031053876504302025, -0.010868262499570847, -0.12908387184143066, 0.04362398758530617, -0.10231366753578186, 0.0024808377493172884, -0.006700460333377123, 0.034293342381715775, -0.11786942929029465, -0.021301807835698128, 0.03097422420978546, -0.03347509726881981, 0.0008423428516834974, -0.05566878244280815, -0.04570099711418152, 0.027116525918245316, -0.05621066316962242, 0.09790375083684921, 0.16200777888298035, 0.09106883406639099, -0.08310148119926453, 0.04068434238433838, -0.047065574675798416, -0.05914062261581421, 0.06375866383314133, 0.04834301769733429, -0.09180818498134613, -0.00043348781764507294, 0.009716524742543697, -0.015789709985256195, 0.0914713516831398, -0.06326659023761749, 0.07828302681446075, -0.004961980972439051, -0.024129590019583702, 0.10685881227254868, 0.1664363145828247, 0.09363000094890594, 0.05023488029837608, 0.0072051752358675, -0.21196863055229187, -0.11530300974845886, 0.05800557881593704, -0.06281768530607224, -0.011303250677883625, 0.09431024640798569, 0.037723608314991, -8.747385375662388e-33, -0.10333184152841568, -0.11165748536586761, -0.18508729338645935, 0.09348724782466888, 0.21974194049835205, -0.06782958656549454, -0.01583845168352127, -0.10349130630493164, 0.07705143094062805, 0.05679308623075485, 0.10163101553916931, -0.06450887769460678, -0.01557808369398117, -0.06077108159661293, 0.06418664753437042, 0.11870589852333069, 0.016794614493846893, -0.16010335087776184, -0.022466128692030907, 0.11729760468006134, 0.12171376496553421, 0.21641850471496582, -0.15899595618247986, -0.06563176959753036, 0.011388964019715786, 0.2831895351409912, 0.030296500772237778, 0.19487839937210083, 0.11804097890853882, -0.0479971244931221, -0.0909322053194046, 0.01660444214940071, -0.13125061988830566, 0.027989590540528297, -0.014302483759820461, 0.027889616787433624, -0.034785158932209015, -0.20514780282974243, -0.04393405839800835, -0.1543518304824829, 0.1419084370136261, 0.0427255854010582, 0.0021389182657003403, -0.04747752472758293, -0.06931803375482559, 0.0016527855768799782, 0.029979266226291656, -0.006697176955640316, 0.030778545886278152, -0.12642541527748108, 0.03743074834346771, 0.1315862238407135, -0.05658791959285736, 0.07550868391990662, -0.13778647780418396, 0.05544893816113472, 0.12931670248508453, 0.02923332154750824, -0.1500265896320343, -0.06071559339761734, 0.04127180576324463, -0.010212213732302189, 0.08993290364742279, 0.04713209718465805, -0.1653464436531067, 0.0837009847164154, 0.21435712277889252, 0.15599708259105682, -0.14286381006240845, -0.05518343672156334, -0.04443482682108879, 0.018383650109171867, -0.07513037323951721, -0.16715067625045776, -0.12343044579029083, 0.042153749614953995, -0.0789632648229599, -0.04693492501974106, -0.15472370386123657, -0.19794708490371704, 0.03809752315282822, -0.05154594033956528, 0.08682288229465485, 0.08870312571525574, 0.09478823840618134, -0.02913947030901909, -0.04281694069504738, -0.08779721707105637, -0.06111268699169159, 0.13238269090652466, -0.18508224189281464, 0.006721168290823698, -0.13169854879379272, 0.16694925725460052, -0.15477976202964783, -1.00224355037426e-07, 0.042507704347372055, 0.00014510913752019405, 0.0464567206799984, -0.10740144550800323, 0.12450702488422394, -0.14779342710971832, 0.03091464564204216, 0.1760290265083313, 0.04906308650970459, 0.10286246985197067, 0.047507718205451965, 0.06959663331508636, -0.05282353609800339, 0.14092755317687988, 0.007914004847407341, 0.061633750796318054, -0.05469570308923721, 0.0629323422908783, -0.03192376345396042, 0.011479421518743038, 0.12660957872867584, -0.03981778770685196, 0.04325057193636894, -0.13231033086776733, -0.02266458235681057, -0.11063215136528015, 0.021078122779726982, 0.06883247196674347, 0.03168613463640213, -0.07889170944690704, -0.0795164406299591, 0.12255562841892242, 0.19329607486724854, -0.03716754540801048, 0.05320928990840912, -0.1248425543308258, 0.16154490411281586, -0.05081147328019142, -0.007349476218223572, 0.038261622190475464, -0.014726171270012856, 0.06844121217727661, -0.17222031950950623, -0.035012051463127136, -0.02015877142548561, -0.21963870525360107, -0.020039139315485954, -0.1983916461467743, 0.0995287299156189, 0.04403093457221985, 0.0833277553319931, -0.0036136237904429436, 0.07470934092998505, 0.2378123700618744, 0.09422517567873001, 0.07876019179821014, 0.03214292228221893, -0.003328959457576275, -0.014335593208670616, 0.23291438817977905, 0.03565794229507446, -0.2845430374145508, 0.07011090964078903, 0.021229824051260948], "changes": {"1wk": -3.977352138257167}}, {"text": "Here's Why Haemonetics (HAE) is a Strong Value Stock Zacks Equity Research Fri, Jan 24, 2025, 5:40 PM 2 min read In This Article: HAE -4.20% For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Haemonetics (HAE) Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company\u2019s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. Blood and its components (plasma, platelets, and red cells) have several vital and frequently life-saving clinical applications. HAE is a Zacks Rank #2 (Buy) stock, with a Value Style Score of B and VGM Score of B. Shares are currently trading at a forward P/E of 15.9X for the current fiscal year compared to the Medical - Products industry's P/E of 18.9X. Additionally, HAE has a PEG Ratio of 1.1 and a Price/Cash Flow ratio of 12X. Value investors should also note HAE's Price/Sales ratio of 2.7X. Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.00 to $4.59 per share. HAE has an average earnings surprise of 2.8%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding HAE to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-24T14:40:11+00:00", "sentiment": {"score": 0.48546381387859583, "confidence": 0.4981735646724701, "probabilities": {"positive": 0.4981735646724701, "negative": 0.012709750793874264, "neutral": 0.4891166687011719}}, "embedding": [-0.08774873614311218, 0.04894496873021126, -0.07689200341701508, -0.017530757933855057, -0.1359824687242508, 0.020756369456648827, 0.03629683703184128, 0.18313360214233398, 0.0992378443479538, 0.031052542850375175, -0.11206910014152527, 0.10387341678142548, -0.11423951387405396, -0.06312635540962219, -0.0361911803483963, -0.0417659617960453, 0.07477931678295135, 0.006856013089418411, -0.15887542068958282, -0.009894922375679016, -0.044849902391433716, -0.021978940814733505, 0.010624589398503304, 0.0006597968749701977, 0.011350320652127266, -0.029866915196180344, -0.07309001684188843, 0.023198137059807777, -0.07365351915359497, -0.07756684720516205, -0.008665834553539753, 0.06253686547279358, 0.19887372851371765, -0.05058516561985016, -0.1751503199338913, 0.0384698212146759, -0.06252504140138626, -0.02371133863925934, -0.03738230839371681, 0.07080820202827454, 0.045916397124528885, -0.02077283337712288, -0.07402316480875015, 0.025688717141747475, -0.06771738827228546, -0.10125233232975006, 0.06806797534227371, -0.049634575843811035, 0.03310859575867653, 0.07654203474521637, -0.22602230310440063, -0.013188524171710014, -0.049333035945892334, -0.05081108212471008, -0.17504948377609253, 0.169061079621315, -0.1268380880355835, -0.09135651588439941, 0.08153998851776123, -0.06862124055624008, -0.0955025851726532, 0.015209954231977463, 0.123252272605896, 0.00567108066752553, 0.12632744014263153, -0.09330663830041885, 0.05019748583436012, 0.035001058131456375, -0.0034115631133317947, -0.0536673367023468, 0.11048725247383118, -0.07624586671590805, -0.08829204738140106, 0.0627673864364624, -0.0870315432548523, 0.10865890234708786, 0.09511537104845047, -0.00858722347766161, 0.0520133450627327, -0.0503382533788681, 0.06274999678134918, 0.006517789792269468, 0.10495595633983612, 0.0715455487370491, 0.0609065517783165, 0.066883884370327, 0.01391427218914032, 0.02434300072491169, 0.026994090527296066, 0.052613358944654465, 0.11233027279376984, -0.03686336427927017, -0.024198368191719055, -0.07147151231765747, 0.10626554489135742, 0.05763063207268715, -0.07501377910375595, 0.020117491483688354, -0.034431710839271545, -0.003875690046697855, 0.12988464534282684, 0.025134790688753128, -0.0161731019616127, -0.010133882984519005, 0.06566572189331055, -0.129897803068161, 0.05328790843486786, -0.12473081797361374, 0.1206037774682045, -0.009913621470332146, -0.07424341887235641, 0.14633311331272125, -0.034141890704631805, -0.07351849973201752, -0.002387715969234705, 0.08634792268276215, -0.03286198899149895, -0.018917080014944077, 0.09284646809101105, 0.06861734390258789, 0.08973897993564606, 0.017348501831293106, 0.09697504341602325, -0.0799843892455101, 0.05459696054458618, -0.04937367141246796, -0.12822464108467102, 1.0236379661745164e-32, -0.11963914334774017, 0.09242618083953857, 0.0558050312101841, -0.014689944684505463, -0.09843792021274567, -0.023682549595832825, -0.06056777387857437, 0.0007703888695687056, -0.02864152006804943, 0.0030855266377329826, -0.06300157308578491, 0.088066965341568, -0.03226234391331673, -0.010649195872247219, -0.011504117399454117, -0.06866084039211273, -0.078440360724926, 0.05389997363090515, -0.001739487168379128, -0.03523476421833038, -0.06719731539487839, -0.025534311309456825, 0.03407421335577965, 0.02998584881424904, -0.045603763312101364, -0.039202019572257996, -0.05051469802856445, 0.11297614127397537, -0.06275321543216705, -0.003608908737078309, 0.021725675091147423, -0.052214086055755615, 0.026930127292871475, -0.20381294190883636, -0.09219242632389069, -0.0536540150642395, -0.14734122157096863, -0.04053160175681114, 0.08421388268470764, 0.047873105853796005, -0.11954793334007263, 0.1322128176689148, -0.11590643227100372, -0.043692950159311295, 0.06567032635211945, -0.037679221481084824, -0.04872291162610054, -0.05315660685300827, -0.03142598271369934, 0.0016963916132226586, -0.1282508373260498, -0.060656677931547165, 0.12852692604064941, -0.0019030903931707144, -0.005604095757007599, 0.06674681603908539, 0.034502897411584854, -0.057126592844724655, -0.07548833638429642, 0.08261870592832565, 0.06526486575603485, 0.09523336589336395, -0.03252366557717323, 0.004683004692196846, -0.0860394537448883, 0.21320806443691254, -0.025339778512716293, 0.023474672809243202, -0.017574818804860115, 0.09878017008304596, 0.09202002733945847, 0.026408232748508453, 0.041441380977630615, -0.11743268370628357, -0.02851524017751217, -0.05021023005247116, -0.06546540558338165, 0.08341187238693237, 0.029986707493662834, -0.04793938249349594, 0.05690542981028557, 0.010359786450862885, -0.03645174950361252, 0.07737269252538681, 0.019527049735188484, -0.007523424457758665, 0.12056232988834381, -0.049124546349048615, -0.11255525052547455, -0.012017058208584785, 0.05723174288868904, -0.11006659269332886, -0.02190195396542549, -0.019966673105955124, 0.07006023824214935, -8.938930710760942e-33, -0.09601971507072449, 0.0007297741249203682, -0.0786653459072113, 0.034529950469732285, 0.044803984463214874, 0.02504027634859085, 0.11869704723358154, -0.03579988330602646, -0.06424875557422638, -0.00176958367228508, 0.08048051595687866, 0.09346788376569748, -0.1606193333864212, -0.03675681725144386, 0.0020415131002664566, 0.03236047178506851, -0.07271280139684677, -0.09440948069095612, -0.001456839730963111, -0.05643600970506668, 0.06025335565209389, 0.15626299381256104, -0.013515662401914597, 0.09246978163719177, 0.00444274116307497, 0.016560139134526253, -0.09492512047290802, -0.02477802149951458, 0.05205000191926956, -0.017675383016467094, -0.08788444101810455, -0.008537322282791138, -0.06499006599187851, 0.0038546272553503513, -0.09224259108304977, -0.0735466405749321, 0.05497116968035698, -0.06374771147966385, -0.002100941725075245, -0.0013551879674196243, 0.11320903897285461, -0.04484296217560768, 0.14955180883407593, -0.02944112755358219, -0.026463227346539497, 0.1792537271976471, 0.08191881328821182, -0.013140421360731125, 0.06257946044206619, 0.02743999846279621, 0.04146430268883705, 0.08230806887149811, -0.08660301566123962, 0.12912589311599731, -0.12234976887702942, -0.03646993264555931, -0.07004866003990173, -0.002930217422544956, -0.17400863766670227, -0.06381893157958984, 0.03211696445941925, 0.11256542056798935, -0.03237013518810272, 0.15375953912734985, 0.012062512338161469, 0.03708707541227341, 0.008403723128139973, 0.043442755937576294, -0.0991353690624237, -0.06363935768604279, -0.004407430067658424, 0.003723062574863434, 0.15411457419395447, -0.09961029887199402, -0.03145367652177811, 0.08904091268777847, 0.023710472509264946, -0.08011235296726227, -0.0070303441025316715, 0.0029493237379938364, -0.09004833549261093, -0.05350988730788231, -0.07310959696769714, 0.07222631573677063, -0.05967969447374344, 0.0025319610722362995, 0.0598347932100296, -0.005501421168446541, 0.009851522743701935, -0.014136984013020992, -0.05754084512591362, -0.07804615050554276, -0.08730224519968033, 0.013614142313599586, -0.05112390220165253, -1.0069275901969377e-07, -0.011193164624273777, -0.18857453763484955, -0.006470104679465294, -0.05482832342386246, -0.001847345381975174, -0.08064310997724533, -0.13582928478717804, 0.05075394734740257, 0.04468144103884697, 0.24435165524482727, 0.0511571429669857, 0.12442301213741302, -0.19678813219070435, -0.038205213844776154, 0.007104428485035896, -0.058832988142967224, -0.02158263884484768, 0.07633833587169647, -0.0062913186848163605, -0.0754927471280098, 0.07074592262506485, 0.10289771854877472, 0.021698445081710815, 0.01963546685874462, 0.10526084154844284, 0.011763102374970913, 0.004636920057237148, -0.1262536495923996, 0.01785016618669033, 0.028732504695653915, 0.12526707351207733, 0.050845302641391754, 0.2027202844619751, 0.07780018448829651, 0.07118949294090271, -0.011742169968783855, 0.07039423286914825, 0.055864039808511734, 0.01968200132250786, 0.13789592683315277, -0.0450148768723011, 0.01168627105653286, -0.05551169067621231, 0.03734181076288223, 0.03773649409413338, 0.01443200372159481, -0.02267903834581375, 0.0869322419166565, 0.07266037166118622, -0.21499577164649963, -0.015716765075922012, -0.012238210998475552, -0.014093141071498394, -0.00659696152433753, -0.021281354129314423, 0.04459856450557709, 0.0036379676312208176, -0.01784493960440159, -0.04367188736796379, 0.025729358196258545, 0.2039184868335724, -0.0657728910446167, 0.009673496708273888, 0.0846225917339325], "changes": {"1wk": -2.499289255427325}}, {"text": "CALID Arm Growth to Support Bruker Shares Amid Macro Issues Zacks Equity Research Fri, Jan 24, 2025, 6:05 PM 5 min read In this article: BRKR -2.48% HAE -4.20% Bruker \u2019s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company\u2019s operations face the wrath of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold). Factors Driving Bruker's Growth The CALID segment has been gaining from strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. In 2024, the company unveiled the flagship timsTOF Ultra 2, featuring significantly enhanced sensitivity for single-cell proteomics and immunopeptidomics. It offers new possibilities in subcellular proteomics. Bruker also introduced the neofleX MALDI-TOF/TOF multiomic Mass Spec Imaging Benchtop system, which is set to enable multiomic colocalization on the tissue of proteins, lipids, metabolites and glycosylation. Earlier this year, Bruker augmented its molecular microscopy portfolio by acquiring Nanophoton, adding a broad range of state-of-the-art Raman microscopy systems. Furthermore, the acquisition of Tornado Spectral Systems in January aims to significantly expand Bruker\u2019s biopharma PAT (Process Analytical Technology) product portfolio range. Within the BSI Nano segment, Bruker has enhanced its materials science research portfolio with the acquisition of Nion by adding a high-end STEM (scanning transmission electron microscope) technology. It also completed the acquisition of Phasefocus Holdings Limited, the developer of a novel optical microscope called Livecyte for label-free imaging. In May 2024, the company purchased NanoString Technologies\u2019 assets, bringing innovative platforms and solutions for spatial transcriptomics and gene expression analysis into the NANO segment. Further, Bruker is strategically progressing with its BioSpin products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. The company\u2019s SciY platform, which offers a comprehensive, vendor-agnostic suite of software and automation solutions for life science industry customers, primarily in the biopharma sector, has been seeing greater adoption. \u00a0In addition, the division also benefits from enabling access to its high-performance GHz (gigahertz) NMR (Nuclear Magnetic Resonance) technology. Story continues Bruker Corporation Price Bruker Corporation Price Bruker Corporation price | Bruker Corporation Quote Concerning Factors for BRKR Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions, including conflicts in Russia and Ukraine, Israel, Palestine and surrounding areas, tensions between the United States and China, potential energy shortages in Europe and increased energy and transportation costs are impacting the company\u2019s operational results. In addition, supply-chain risks associated with inflation, the threat of recession, currency volatility, and the worldwide shortage of semiconductor chips, components and raw materials such as copper also persist. All these issues are leading to higher costs and expenditures for the company and putting pressure on profitability. In the third quarter, Bruker\u2019s cost of revenues increased by 23.8% compared with the same period in 2023. Selling, general and administrative (SG&A) expenses surged 30.2%. Bruker generates a substantial portion of its revenues from international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.\u00a0 As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. In addition, currency fluctuations could cause the price of Bruker\u2019s products to be less competitive than its principal competitors' offerings. Moreover, Bruker faces substantial competition in a consolidating industry and expects competition in all its markets to increase further. Bruker BioSpin competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin faces competitive threats from Perkin Elmer, Mediso, Trifoil, MR Solutions, RS2D, Visualsonics (Fuji Film) and others. The stock has lost 9.4% in the past six months compared with the industry\u2019s 8.4% fall. With the company currently focusing on core business expansion through innovations, new offerings and expansion into new markets, we expect the stock to regain momentum in the coming days. Key Picks Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Penumbra PEN and Haemonetics HAE. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Penumbra and Haemonetics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Phibro Animal Health\u2019s shares have risen 86.2% in the past year. Estimates for the company\u2019s fiscal 2025 earnings per share have remained constant at $1.62 in the past 30 days. PAHC\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it posted an earnings surprise of 52.17%. Estimates for Penumbra\u2019s 2024 earnings per share have remained constant at $2.81 in the past 30 days. Shares of the company have risen 4.3% in the past year compared with the industry\u2019s 7.2% rise. PEN\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%. In the last reported quarter, it delivered an earnings surprise of 23.19%. Estimates for Haemonetics\u2019 fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have declined 5.9% in the past year against the industry\u2019s growth of 4.7%. HAE\u2019s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View comments Terms and Privacy Policy Privacy Dashboard Recommended stories", "symbol": "HAE", "date": "2025-01-24T15:05:00+00:00", "sentiment": {"score": 0.7991603957489133, "confidence": 0.807788074016571, "probabilities": {"positive": 0.807788074016571, "negative": 0.008627678267657757, "neutral": 0.18358412384986877}}, "embedding": [-0.1288096159696579, -0.16716310381889343, -0.14013436436653137, -0.15714383125305176, 0.06826651841402054, -0.11167879402637482, -0.05328766256570816, 0.15574753284454346, 0.06716547161340714, 0.08543871343135834, -0.015524966642260551, -0.04308610409498215, -0.0318414568901062, 0.07514426857233047, -0.0017194133251905441, 0.05874387174844742, -0.11023882031440735, 0.03031924180686474, -0.142310231924057, 0.06476135551929474, 0.09224539995193481, -0.08370644599199295, 0.014967374503612518, 0.025052981451153755, -0.11583907902240753, 0.03327599912881851, -0.041796550154685974, -0.038021937012672424, -0.19549337029457092, -0.004223327152431011, 0.10213152319192886, 0.21175353229045868, -0.026937080547213554, -0.010204361751675606, 0.053394027054309845, 0.026929527521133423, -0.05728583037853241, 0.06471632421016693, -0.06033746525645256, -0.06160876899957657, 0.010705839842557907, -0.009339339099824429, -0.10777676850557327, -0.08169345557689667, 0.07289378345012665, -0.07826980948448181, -0.00205867737531662, -0.018774893134832382, 0.07399415969848633, 0.09319102764129639, -0.13684140145778656, -0.06354955583810806, -0.037480223923921585, 0.122073233127594, -0.017553433775901794, 0.10652247071266174, -0.04240892454981804, -0.006919218227267265, 0.12365745007991791, 0.005324880592525005, 0.030883174389600754, -0.03268563374876976, 0.050751082599163055, -0.07114662230014801, 0.11673787236213684, 0.0351531058549881, 0.04845242202281952, 0.0021245982497930527, -0.040621981024742126, -0.01929294317960739, -0.02286665514111519, -0.027067318558692932, 0.052894167602062225, 0.22528326511383057, -0.014032385312020779, 0.07440833747386932, 0.14863914251327515, 0.09301629662513733, 0.08309341967105865, -0.018581576645374298, 0.1055954173207283, 0.10815666615962982, 0.1876419186592102, 0.02276935800909996, -0.03785376995801926, 0.08931523561477661, 0.05343809723854065, 0.16082336008548737, -0.028900999575853348, 0.0313064381480217, 0.08691693842411041, -0.014864726923406124, -0.011016793549060822, -0.04434563219547272, -0.07012291252613068, -0.02732839062809944, 0.050472065806388855, -0.0006236070767045021, 0.13174210488796234, -0.06125856190919876, -0.027380136772990227, -0.02317151054739952, 0.03250304237008095, -0.0347764678299427, -0.0772719606757164, -0.0812302902340889, 0.07126696407794952, 0.07264354825019836, 0.14225246012210846, 0.0871148407459259, 0.1015971451997757, 0.12090097367763519, 0.0028008557856082916, -0.04201414808630943, 0.038467392325401306, 0.11806446313858032, -0.08188745379447937, 0.026336291804909706, 0.15852507948875427, -0.05209154635667801, -0.0043157609179615974, 0.10452065616846085, 0.0016926825046539307, -0.08368019759654999, 0.05375129356980324, 0.1650499403476715, -0.1026684120297432, 8.239730507844521e-33, 0.07497994601726532, 0.07178404927253723, 0.03867679834365845, 0.015489835292100906, -0.18280714750289917, -0.16497576236724854, -0.0488252267241478, 0.011777320876717567, -0.14581644535064697, -0.10758724808692932, -0.010025124996900558, 0.11115339398384094, -0.005615685135126114, 0.06583098322153091, 0.08847367763519287, -0.10066842287778854, -0.03400295972824097, 0.07125264406204224, 0.05661330372095108, -0.05215207487344742, -0.09193683415651321, -0.07430388778448105, -0.0004841834306716919, 0.0032447222620248795, 0.0016423650085926056, 0.10796249657869339, -0.008281314745545387, -0.03230765834450722, 0.006578776985406876, 0.011420393362641335, -0.05105914548039436, 0.057622719556093216, 0.021205123513936996, -0.06680694222450256, 0.14123407006263733, -0.09200453758239746, -0.05038755014538765, -0.045984234660863876, -0.03595135733485222, 0.06779654324054718, 0.03887992352247238, 0.03553865849971771, -0.09593081474304199, -0.09306371212005615, 0.01615089923143387, -0.1156798005104065, -0.15744906663894653, 0.10022786259651184, 0.06706724315881729, -0.04068463295698166, -0.072877898812294, 0.01611994579434395, 0.06609141826629639, -0.02498394250869751, -0.08425726741552353, 0.12723365426063538, -0.04283458739519119, -0.23634463548660278, 0.13953173160552979, 0.05055335909128189, -0.06316964328289032, -0.012163655832409859, 0.030593205243349075, 0.19020569324493408, 0.007557880133390427, 0.04797891527414322, -0.13590389490127563, 0.03591316193342209, -0.0515313521027565, 0.16073718667030334, -0.047894299030303955, -0.04333530738949776, 0.3355066776275635, -0.04880964010953903, 0.20472672581672668, 0.0363999679684639, 0.07369266450405121, 0.008368641138076782, -0.13800063729286194, 0.13802331686019897, -0.02472040243446827, 0.055311016738414764, -0.1005028560757637, -0.05615214630961418, -0.14848476648330688, 0.01981523260474205, 0.01900622621178627, -0.08024485409259796, -0.0877954289317131, -0.07114345580339432, 0.06753677129745483, -0.1468321532011032, -0.13780459761619568, -0.01669136993587017, -0.15773722529411316, -7.525378182746002e-33, 0.023493953049182892, -0.14348182082176208, -0.05864008143544197, -0.015486571937799454, 0.07359381020069122, 0.057883307337760925, 0.07882146537303925, -0.08792738616466522, 0.008369192481040955, -0.1084197610616684, 0.10771004110574722, 0.0653134435415268, -0.09661051630973816, -0.11182945966720581, -0.02674052119255066, 0.09630944579839706, -0.10728789865970612, -0.044579312205314636, 0.04083171486854553, 0.01323023997247219, 0.01702303998172283, 0.16254185140132904, -0.032124850898981094, 0.06372077763080597, -7.623655255883932e-05, -0.007951389998197556, 0.005763017572462559, -0.022187545895576477, 0.07593477517366409, 0.08204512298107147, -0.08409573137760162, 0.03336884081363678, -0.0958489179611206, -0.0015692338347434998, 0.011532433331012726, 0.0009148921817541122, -0.014469695277512074, -0.22999761998653412, 0.006659924518316984, -0.04924739524722099, 0.04205919802188873, 0.06603096425533295, -0.11291341483592987, -0.025978468358516693, 0.12074074149131775, 0.13115113973617554, 0.007162034511566162, 0.017860116437077522, 0.13275699317455292, 0.04377826303243637, 0.00591430626809597, 0.04119786247611046, -0.034192800521850586, -0.0580991692841053, -0.0026251100935041904, -0.014116223901510239, 0.07013869285583496, 0.019153553992509842, -0.08097483217716217, 0.0003924071788787842, -0.0035575348883867264, -0.04323522374033928, 0.08424177765846252, 0.0012679863721132278, 8.923187851905823e-05, 0.12023330479860306, 0.0550965890288353, -0.04185759648680687, 0.03566586226224899, -0.0854492038488388, -0.0073140948079526424, -0.0774136558175087, 0.257364422082901, 0.010899825021624565, 0.029058635234832764, 0.018602903932332993, -0.1192321628332138, -0.08379779756069183, -0.14748112857341766, 0.0671832337975502, -0.01595858857035637, 0.04211109131574631, 0.017483817413449287, -0.0041679204441607, 0.12388624995946884, 0.051812298595905304, -0.08876366168260574, 0.034764889627695084, -0.10990339517593384, -0.07754416018724442, -0.04365827143192291, -0.1388692855834961, -0.05876985937356949, 0.08805541694164276, 0.03135199099779129, -9.96710056710981e-08, 0.16961967945098877, -0.059030093252658844, 0.01219976507127285, -0.1510581523180008, -0.06414351612329483, 0.019574031233787537, 0.07434207201004028, 0.0889473557472229, 0.050592321902513504, 0.12485489249229431, 0.020410701632499695, 0.04402369260787964, -0.18947483599185944, 0.03727862238883972, 0.056937672197818756, 0.08877624571323395, 0.03918140381574631, -0.15010975301265717, -0.12236298620700836, -0.12198193371295929, -0.031859252601861954, 0.04989462345838547, 0.0019118990749120712, -0.04228174686431885, 0.036974284797906876, -0.03437696769833565, -0.0833420604467392, 0.046874143183231354, -0.004623748827725649, -0.1524040549993515, 0.017057834193110466, 0.010098368860781193, 0.001223803497850895, 0.0834331139922142, 0.08797261118888855, 0.015168935060501099, -0.06111301854252815, 0.0909799337387085, -0.06851057708263397, 0.16619715094566345, -0.09564797580242157, -0.05322423577308655, -0.18684831261634827, 0.0035354159772396088, -0.04953881725668907, -0.0032680281437933445, -0.09369092434644699, 0.07432059943675995, -0.03598855435848236, -0.025857102125883102, -0.029033612459897995, -0.061031557619571686, -0.0726190060377121, -0.014091674238443375, -0.07311451435089111, 0.26671645045280457, -0.029387135058641434, -0.1114969551563263, 0.05967448651790619, -0.008968234993517399, 0.09483551234006882, -0.13124166429042816, 0.06996942311525345, -0.035776473581790924], "changes": {"1wk": -2.499289255427325}}, {"text": "HAE or ABT: Which Is the Better Value Stock Right Now? Zacks Equity Research Mon, Jan 20, 2025, 7:40 PM 2 min read In This Article: HAE -4.20% ABT +0.41% Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Right now, both Haemonetics and Abbott are sporting a Zacks Rank of # 2 (Buy). This means that both companies have witnessed positive earnings estimate revisions, so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook. But this is just one piece of the puzzle for value investors. Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use. HAE currently has a forward P/E ratio of 16.01, while ABT has a forward P/E of 22.08. We also note that HAE has a PEG ratio of 1.14. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABT currently has a PEG ratio of 2.43. Another notable valuation metric for HAE is its P/B ratio of 4.28. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ABT has a P/B of 4.92. These are just a few of the metrics contributing to HAE's Value grade of B and ABT's Value grade of C. Both HAE and ABT are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that HAE is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-20T16:40:08+00:00", "sentiment": {"score": 0.07021023519337177, "confidence": 0.08635967969894409, "probabilities": {"positive": 0.08635967969894409, "negative": 0.01614944450557232, "neutral": 0.897490918636322}}, "embedding": [-0.12601228058338165, -0.02915382944047451, -0.10102438181638718, 0.01128261536359787, -0.08898739516735077, 0.0656956136226654, 0.05288783833384514, 0.22206702828407288, 0.17616882920265198, 0.019272301346063614, -0.1310984492301941, 0.03776851296424866, -0.06016229838132858, -0.06316246092319489, 0.023458153009414673, 0.012277781963348389, 0.13725082576274872, -0.020832963287830353, -0.0900159403681755, 0.01618427038192749, -0.04690094664692879, 0.0012181843630969524, 0.09437917917966843, 0.027626775205135345, 0.14763243496418, -0.04720841348171234, 0.011199329048395157, 0.05770474672317505, -0.1249050498008728, -0.18537576496601105, -0.04928874969482422, 0.1283910870552063, 0.19332394003868103, -0.11033765226602554, -0.13798299431800842, -0.005731228739023209, -0.016260746866464615, -0.01116609200835228, 0.11602324992418289, -0.0006376850651577115, 0.003642958588898182, 0.07653315365314484, 0.0030338175129145384, 0.027674466371536255, -0.12916773557662964, -0.1352732926607132, 0.05156286805868149, -0.04657900333404541, -0.058915168046951294, 0.056391119956970215, -0.14066079258918762, 0.04941421002149582, -0.09745204448699951, 0.027023393660783768, -0.0810258537530899, 0.12891483306884766, -0.10661981254816055, -0.10026755928993225, 0.12144919484853745, -0.035042885690927505, -0.07225504517555237, 0.061529286205768585, 0.1199880838394165, -0.017714370042085648, 0.13626998662948608, 0.03571927174925804, -0.02658679708838463, 0.015137549489736557, -0.12466458976268768, -0.028413720428943634, 0.04389641806483269, -0.0951276570558548, -0.16585686802864075, 0.006117063574492931, -0.07614108920097351, 0.0894552618265152, 0.06042616814374924, 0.035076700150966644, -0.00641053169965744, -0.10169477760791779, 0.05496188998222351, 0.018617961555719376, 0.035619597882032394, -0.036735810339450836, 0.1021188423037529, -0.029516451060771942, 0.07716917991638184, 0.017474666237831116, 0.043985556811094284, -0.009200358763337135, 0.0835065096616745, -0.05708002671599388, -0.041437454521656036, -0.056756578385829926, 0.16528069972991943, 0.05536539852619171, -0.07919811457395554, -0.007524278946220875, -0.04886845871806145, 0.039474960416555405, 0.08723229169845581, 0.09907853603363037, -0.08568350970745087, -0.0866764634847641, 0.11402346193790436, -0.10559625923633575, 0.12968076765537262, -0.11282780766487122, 0.18071550130844116, -0.05711350217461586, -0.002919401042163372, 0.11110779643058777, -0.06837327778339386, -0.056442759931087494, -0.0160130076110363, 0.04316125810146332, 0.008154629729688168, -0.025652360171079636, 0.09498293697834015, -0.07353121042251587, 0.08563725650310516, 0.04629366099834442, 0.18562889099121094, -0.056953493505716324, 0.015595989301800728, -0.11587141454219818, -0.22947193682193756, 1.3749168205024947e-32, -0.08695901185274124, 0.046162333339452744, 0.009298368357121944, -0.08235928416252136, -0.07896612584590912, -0.01693662628531456, -0.08924861252307892, 0.010745152831077576, -0.029057534411549568, -0.05249486491084099, -0.05501364916563034, 0.134902685880661, -0.01968528889119625, -0.1860465407371521, 0.08690111339092255, -0.08606736361980438, -0.09533946961164474, 0.07119851559400558, -0.029743805527687073, -0.042882759124040604, -0.03379201889038086, 0.05926840752363205, -0.006109599024057388, 0.038592927157878876, 0.0829918384552002, -0.12100118398666382, 0.016027148813009262, 0.06557175517082214, -0.15190225839614868, 0.01036851853132248, 0.0670841783285141, 0.006037178449332714, 0.007374688982963562, -0.13454945385456085, -0.15575271844863892, -0.12858110666275024, -0.15352852642536163, 0.002494458109140396, 0.07126976549625397, 0.00769470538944006, -0.14241892099380493, 0.08909950405359268, -0.1386139988899231, -0.022759171202778816, 0.02987471967935562, -0.010996444150805473, -0.049143485724925995, 0.04035505652427673, 0.01089679729193449, 0.014961259439587593, -0.08169515430927277, -0.02980368584394455, 0.008186880499124527, -0.013014390133321285, -0.12004389613866806, 0.05708496272563934, 0.03032604791224003, -0.07133705914020538, -0.0460851788520813, 0.1399008184671402, 0.10956908762454987, 0.17836351692676544, 0.015450404956936836, -0.11164066195487976, -0.1922173798084259, 0.20644459128379822, -0.03011896088719368, 0.021564766764640808, 0.03891988471150398, 0.13303421437740326, 0.053785040974617004, -0.014027213677763939, 0.1317911297082901, -0.10753636062145233, -0.02720966562628746, -0.02544061280786991, 0.01035850029438734, 0.07290715724229813, 0.06575246900320053, 0.01357670221477747, -0.020459197461605072, 0.010634563863277435, 0.019296638667583466, 0.0002311314456164837, -0.08431649953126907, -0.08127227425575256, 0.13511693477630615, -0.013701580464839935, -0.10185034573078156, 0.021933933719992638, 0.022894177585840225, -0.018734967336058617, -0.05613488331437111, 0.0030163563787937164, 0.05420400947332382, -1.1118292094397678e-32, -0.003710124408826232, 0.02783067896962166, -0.0049091787077486515, 0.10866259038448334, -0.025996793061494827, -0.04839706793427467, 0.23163637518882751, -0.032243773341178894, -0.056026529520750046, -0.05557945370674133, 0.09200924634933472, 0.051455192267894745, -0.15238991379737854, -0.055356867611408234, 0.05673855543136597, -0.011585244908928871, -0.06831411272287369, -0.1297454684972763, 0.07381826639175415, 0.021623780950903893, 0.132603257894516, 0.20051079988479614, -0.08317963778972626, 0.126027449965477, -0.053933996707201004, 0.11038991808891296, -0.03829047828912735, -0.007683934643864632, -0.0052309222519397736, -0.031097188591957092, -0.043713152408599854, 0.06299026310443878, -0.03426172956824303, -0.002372919348999858, -0.1871808022260666, -0.02422795072197914, 0.10780146718025208, -0.0714019387960434, -0.1471911519765854, 0.02985314466059208, 0.11103738844394684, 0.012369325384497643, -0.04818929731845856, -0.024562757462263107, 0.038866251707077026, 0.12930992245674133, 0.10255368798971176, -0.007047299295663834, 0.09310474991798401, -0.058466557413339615, 0.10523431748151779, 0.008187992498278618, -0.038385551422834396, 0.15843850374221802, -0.19701604545116425, -0.031021999195218086, -0.1226278692483902, 0.03337781876325607, -0.11859820783138275, 0.04490339383482933, 0.031086601316928864, 0.19349372386932373, 0.1488211452960968, 0.09558261930942535, -0.04739059507846832, -0.010974316857755184, -0.04879040643572807, -0.007936802692711353, -0.06755764037370682, -0.03235817700624466, -0.062100883573293686, -0.06173158437013626, 0.19967427849769592, -0.11483623832464218, 0.06034621223807335, 0.1986401081085205, 0.09446460753679276, -0.09792140126228333, -0.04838152602314949, -0.053378716111183167, -0.12548649311065674, 0.05839969590306282, -0.10895083844661713, 0.10765528678894043, -0.18365496397018433, 0.10719749331474304, 0.05470618978142738, -0.06582339107990265, 0.04028104245662689, 0.022698108106851578, -0.12130911648273468, -0.12407387793064117, -0.035272084176540375, -0.05555929243564606, -0.07154133915901184, -1.0050148091522715e-07, -0.05293208360671997, -0.12169298529624939, -0.01291232742369175, -0.0250384621322155, 0.08642430603504181, -0.04797453060746193, -0.13080398738384247, 0.01406153105199337, 0.026392634958028793, 0.21543824672698975, 0.015245381742715836, 0.011305420659482479, -0.2761646509170532, 0.017309918999671936, -0.07880290597677231, 0.03941918909549713, -0.09253673255443573, 0.07457004487514496, -0.010634261183440685, -0.05757454037666321, 0.036334067583084106, 0.11043927073478699, 0.12662053108215332, -0.030774958431720734, 0.0427030585706234, 0.014300834387540817, -0.10647955536842346, -0.1382599025964737, 0.09637834131717682, 0.09468504041433334, 0.16672861576080322, 0.028760336339473724, 0.16254626214504242, 0.04486287385225296, 0.17936307191848755, -0.050693538039922714, 0.05627655237913132, 0.07791317999362946, -0.007289143279194832, 0.2953201234340668, 0.00630219466984272, -0.046052880585193634, -0.04068845883011818, 0.019442513585090637, 0.06664527952671051, -0.06406117975711823, -0.11693502962589264, 0.2062300592660904, 0.030963534489274025, -0.18356725573539734, 0.09903011471033096, -0.10126633197069168, -0.07366743683815002, -0.03382563591003418, -0.02295544743537903, -0.024809813126921654, -0.04712317883968353, -0.03694523498415947, -0.11082757264375687, 0.010707015171647072, 0.25168418884277344, -0.2694488763809204, 0.03671598806977272, 0.15983515977859497], "changes": {"1wk": -5.249863184996497}}, {"text": "IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch Zacks Equity Research Fri, Jan 24, 2025, 3:58 PM 4 min read In This Article: IDXX +11.13% HAE -4.20% IDEXX Laboratories, Inc. IDXX has unveiled the IDEXX Cancer Dx, a first-of-its-kind diagnostic panel with early detection of lymphoma in dogs. This affordable and accessible blood test can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing veterinarians in the United States with actionable results within two to three days. The test is especially crucial for the 20 million dogs in North America who face an increased risk of cancer. Early detection and treatment of canine lymphoma, one of the most common cancers, may help extend the lifespan and improve the quality of life for affected dogs. Predicting IDXX Stock Movement Following the News Following the announcement yesterday, shares of IDEXX edged up 0.4%, finishing at $432.34. The latest solution builds on the company\u2019s more than 40 years of leadership in veterinary research and technology development.\u00a0 IDEXX is leading the charge in early cancer detection for dogs and is eager to expand the IDEXX Cancer Dx to include other cancer types. We expect the latest development to positively boost market sentiment toward the stock. IDEXX currently has a market capitalization of $35.26 billion. The company\u2019s earnings yield of 2.79% compares favorably to the industry\u2019s yield of -3.23%. It delivered an earnings beat of 0.9%, on average, in the trailing four quarters. Significance of IDEXX\u2019s New Panel The IDEXX Cancer Dx panel offers high sensitivity and specificity, yielding reliable results for both sick dogs and routine preventive care for at-risk dogs. Clinicians can add the test to existing diagnostic wellness panels using a single blood sample, reflecting the simplicity aspect. In addition, every IDEXX Cancer Dx result comes with access to IDEXX Medical Consultants, including board-certified oncologists and internists. Pet-owner education materials and resources to support client communications are also provided. Zacks Investment Research Image Source: Zacks Investment Research The test also offers actionable next steps. IDEXX Cancer Dx with lymphoma delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be provided with positive results as available at no additional cost. Moreover, the test now forms part of IDEXX Preventive Care, the most comprehensive portfolio of products and services supporting veterinarians with preventive care. This inclusion unlocks additional insights for at-risk dogs. Industry Prospects Favor IDEXX Per a Research report, the global veterinary diagnostics market was valued at $10.71 billion in 2024 and is expected to witness a compound annual rate of 10.04% up to 2030. Some of the key factors driving the market growth include increased expenditure on animal health, rising incidence of diseases in animals, advancements in diagnostics and an increasing medicalization rate. Story Continues Other Developments in IDEXX In December 2024, IDEXX\u2019s board of directors sanctioned an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the company\u2019s common stock. These shares are in addition to the 1.3 million shares remaining under the company\u2019s ongoing share repurchase program as of Dec. 3, 2024, pursuant to previous board authorizations. IDEXX Stock Price Performance In the past month, IDEXX shares have risen 4.6% compared with the industry\u2019s growth of 7%. IDXX\u2019s Zacks Rank and Key Picks IDEXX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Penumbra PEN and Haemonetics HAE. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Penumbra and Haemonetics each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Phibro Animal Health shares have surged 86.2% in the past year. Estimates for the company\u2019s fiscal 2025 earnings per share have remained constant at $1.62 in the past 30 days. PAHC\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it posted an earnings surprise of 52.17%. Estimates for Penumbra\u2019s 2024 earnings per share have remained constant at $2.81 in the past 30 days. Shares of the company have risen 4.3% in the past year compared with the industry\u2019s 7.2% rise. PEN\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%. In the last reported quarter, it delivered an earnings surprise of 23.19%. Estimates for Haemonetics\u2019 fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have declined 5.9% in the past year against the industry\u2019s growth of 4.7%. HAE\u2019s earnings surpassed estimates in three of the trailing four quarters and broke even in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-24T12:58:00+00:00", "sentiment": {"score": 0.8027713820338249, "confidence": 0.8107024431228638, "probabilities": {"positive": 0.8107024431228638, "negative": 0.007931061089038849, "neutral": 0.18136650323867798}}, "embedding": [-0.03564053773880005, -0.0027698632329702377, 0.07572287321090698, 0.021811891347169876, 0.03277626261115074, -0.09717497229576111, 0.10958787053823471, 0.1367659717798233, 0.1382104754447937, -0.003524964675307274, -0.055056482553482056, 0.16338229179382324, 0.08019670844078064, 0.05020305886864662, -0.12771174311637878, 0.00013469159603118896, 0.036401793360710144, -0.013070506975054741, -0.18037095665931702, 0.07311222702264786, -0.07807649672031403, -0.15107780694961548, 0.11395519971847534, -0.01881071925163269, -0.0627063661813736, -0.05891241878271103, -0.027100440114736557, -0.07884667813777924, -0.15313692390918732, -0.03654429689049721, 0.10333128273487091, 0.11738757789134979, 0.02038039267063141, -0.13825936615467072, -0.10000935941934586, -0.15096843242645264, 0.03989583998918533, 0.08891120553016663, 0.010929572395980358, 0.05305230990052223, 0.045418690890073776, -0.1144544929265976, -0.08471106737852097, 0.00024830829352140427, -0.11176237463951111, -0.23929733037948608, -0.17950326204299927, -0.11073212325572968, 0.09864121675491333, 0.17371410131454468, -0.1430438905954361, -0.16505250334739685, 0.07763738930225372, 0.01969085820019245, -0.12297853827476501, -0.12419068813323975, -0.18677093088626862, -0.06659314036369324, -0.016669267788529396, -0.023521384224295616, 0.0906999409198761, 0.03560905158519745, 0.08994869887828827, 0.0978042483329773, 0.12751972675323486, 0.044358544051647186, -0.05089349299669266, 0.02649778500199318, -0.08464828878641129, -0.1076437383890152, 0.13164028525352478, 0.008169656619429588, -0.059858910739421844, 0.028175942599773407, -0.053303271532058716, 0.08020943403244019, 0.18165673315525055, 0.029654594138264656, 0.2759091854095459, -0.0568682886660099, -0.035553909838199615, 0.11190681904554367, 0.12388162314891815, 0.07821133732795715, -0.009959587827324867, 0.13277751207351685, 0.10086984932422638, 0.12679578363895416, -0.06547851860523224, 0.03688710555434227, 0.07671244442462921, -0.06726613640785217, -0.12929967045783997, 0.027268391102552414, 0.1439601182937622, 0.02901698648929596, -0.09416444599628448, -0.041296377778053284, 0.03105957619845867, 0.036368612200021744, 0.009945236146450043, 0.007026638835668564, -0.05349665880203247, -0.04596444219350815, -0.09323375672101974, -0.1616126298904419, -0.012421241030097008, -0.04194340854883194, 0.013694794848561287, -0.023236017674207687, -0.0947335809469223, 0.0006993357092142105, -0.001956094056367874, -0.006956010591238737, -0.06951379776000977, 0.208757683634758, -0.05936602130532265, -0.08083789795637131, 0.1783755123615265, -0.08086097240447998, 0.1440386325120926, -0.02174980752170086, -0.01815211772918701, 0.05560871958732605, 0.1777910739183426, 0.04331594705581665, -0.08120162785053253, 1.317157436206903e-32, -0.06522322446107864, 0.06231718510389328, -0.04368050396442413, 0.043979886919260025, -0.06765806674957275, -0.016926756128668785, 0.05158037692308426, -0.03199676796793938, -0.19998601078987122, -0.02779427170753479, -0.17054733633995056, 0.19625483453273773, 0.03361346572637558, -0.06422798335552216, -0.03817875683307648, -0.08759833872318268, 0.038769036531448364, 0.11296381056308746, -0.029294177889823914, -0.020376700907945633, 0.029486889019608498, -0.08740226179361343, 0.02880602329969406, -0.036061592400074005, -0.019478363916277885, 0.027609867975115776, -0.1522110104560852, 0.036382924765348434, 0.058951664716005325, 0.04453091695904732, -0.17311131954193115, -0.013832340016961098, 0.03532977029681206, -0.06480999290943146, -0.2224457859992981, 0.05657193064689636, -0.09045015275478363, -0.0935760885477066, 0.08178805559873581, 0.13973011076450348, 0.007891181856393814, 0.06447194516658783, 0.020452262833714485, -0.09103338420391083, 0.023095525801181793, 0.03400867432355881, -0.11550235748291016, -0.09734611213207245, -0.0540282279253006, 0.045776043087244034, -0.04639679193496704, 0.039780184626579285, 0.04870928078889847, -0.12379565834999084, -0.06295013427734375, 0.051131121814250946, -0.05970551446080208, -0.043772272765636444, -0.005395805928856134, 0.1755097359418869, 0.07630867511034012, 0.09390188753604889, -0.04014008119702339, 0.0698905885219574, -0.07481859624385834, 0.03335283696651459, 0.036975085735321045, -0.07066816836595535, -0.14547204971313477, 0.2660605311393738, -0.021262502297759056, 0.00317428819835186, 0.16109538078308105, -0.14807330071926117, 0.1456267386674881, -0.06186579540371895, -0.04637771099805832, 0.10305789113044739, 0.07902014255523682, 0.03422179073095322, 0.1431930661201477, -0.0045907264575362206, -0.10803690552711487, 0.09188581258058548, 0.06485673785209656, 0.05077921226620674, -0.06570325791835785, 0.11089229583740234, -0.1261899620294571, 0.018067531287670135, -0.00022890884429216385, -0.05929958075284958, -0.09540670365095139, 0.06720221042633057, 0.06616407632827759, -1.2484255468303547e-32, -0.12069268524646759, 0.02693444862961769, 0.03725863993167877, -0.0591135248541832, 0.014916193671524525, 0.05906308442354202, 0.11692357808351517, -0.018334006890654564, 0.04122152552008629, 0.1082329973578453, 0.08685746043920517, 0.12092650681734085, -0.06739868223667145, 0.031287383288145065, -0.12773656845092773, 0.025378573685884476, -0.029460566118359566, -0.12557505071163177, -0.02256578952074051, -0.14192724227905273, -0.04816768318414688, 0.2637803852558136, -0.0917874276638031, 0.11194605380296707, -0.09343479573726654, 0.13888108730316162, 0.03108910098671913, 0.11143039166927338, 0.05371592566370964, -0.23975034058094025, -0.12655240297317505, 0.0366605781018734, -0.1240607500076294, 0.05070097744464874, 0.003940196707844734, 0.021835625171661377, 0.09633167088031769, -0.2007046937942505, -0.007541900034993887, -0.03265504539012909, 0.1015116274356842, 0.013435406610369682, -0.013350090011954308, 0.03781130164861679, 0.09703531861305237, 0.096926748752594, 0.054719798266887665, -0.08666360378265381, 0.24750366806983948, 0.10499127209186554, -0.07957585155963898, 0.054270755499601364, -0.02062145620584488, 0.07199761271476746, -0.10446521639823914, 0.013266840018332005, -0.05784708261489868, 0.00022652745246887207, -0.20110857486724854, 0.11139547824859619, -0.02854239195585251, 0.18127520382404327, 0.01839268207550049, 0.14804065227508545, -0.09253167361021042, -0.03555910289287567, -0.005677780136466026, -0.026222363114356995, -0.0007082880474627018, -0.12381329387426376, 0.03481336683034897, 0.07342197746038437, -0.17840524017810822, -0.21542474627494812, -0.029259689152240753, 0.1161375492811203, 0.07727441936731339, -0.10012835264205933, -0.027970947325229645, 0.06623047590255737, -0.0030011015478521585, -0.12372506409883499, 0.08718883991241455, 0.013729092665016651, 0.0600733682513237, 0.145180806517601, -0.06723043322563171, 0.09891315549612045, -0.0783378928899765, -0.07840238511562347, -0.08474337309598923, -0.07739393413066864, -0.06475958228111267, -0.019763551652431488, -0.04416229575872421, -1.0060745836426577e-07, -0.03462878614664078, -0.11051349341869354, -0.03466576337814331, -0.0626349002122879, 0.04800538718700409, -0.026544680818915367, -0.09840693324804306, 0.003808357287198305, 0.07980810105800629, 0.12466225773096085, 0.10005173087120056, 0.04797178506851196, -0.2521147131919861, -0.010974427685141563, -0.06765126436948776, -0.007295720279216766, -0.03468136489391327, 0.011837834492325783, 0.0030092508532106876, 0.028413135558366776, -0.011270534247159958, 0.07342539727687836, 0.12293025851249695, -0.07492603361606598, -0.00301407091319561, -0.10378038883209229, 0.06831943988800049, 0.03142695873975754, -0.04937347024679184, -0.001994788646697998, -0.08750879764556885, -0.012575183063745499, 0.01548854447901249, 0.10461651533842087, 0.08350305259227753, -0.12572242319583893, 0.08616045117378235, 0.06322953850030899, 0.10871622711420059, 0.1616968810558319, 0.06667649000883102, 0.10057858377695084, -0.09437469393014908, -0.042265672236680984, -0.06094697117805481, -0.03584903106093407, -0.11576557904481888, -0.1372656375169754, 0.0720435231924057, -0.23030109703540802, -0.07290533185005188, -0.06865640729665756, 0.0030434229411184788, -0.041803084313869476, -0.034701112657785416, 0.09618513286113739, -0.11931547522544861, -0.058196235448122025, 0.004325062967836857, 0.08551868051290512, 0.15395516157150269, -0.17290861904621124, 0.11333593726158142, 0.07240039855241776], "changes": {"1wk": -1.906239028436139}}, {"text": "Is Thermo Fisher Stock Worth Holding on to in Your Portfolio? Zacks Equity Research Fri, Jan 24, 2025, 4:08 PM 5 min read In This Article: TMO -0.67% HAE -4.20% Thermo Fisher Scientific Inc. \u2019s TMO recent slew of product launches reflects its ongoing commitment to innovation. The company gains early insights into customer needs through its strong partnerships, fueling industry-leading solutions. Strategic acquisitions play an important role as well, expanding Thermo Fisher\u2019s portfolio. Meanwhile, adverse macroeconomic impacts and a fierce competitive landscape may create operational challenges for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 6.4% compared with the industry\u2019s 12.5% growth and the S&P 500 composite\u2019s 26% rise. The renowned medical and laboratory equipment provider has a market capitalization of $219.78 million. TMO\u2019s earnings yield of 4.03% compares favorably to the industry\u2019s -3.23%. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.63%. Let\u2019s delve deeper. Upsides for Thermo Fisher Impressive Product Launches: Thermo Fisher has been actively enhancing its product offerings and strengthening its portfolio. In the third quarter of 2024, the company launched its new pre-transplant risk assessment assay to help assess the risk of early acute rejection in kidney transplant recipients. Earlier, Thermo Fisher unveiled the Scientific KingFisher PlasmidPro Maxi Processor (PlasmidPro) and Scientific One Lambda Laboratories \u2014 a new CXCL10 testing service. It also introduced the Thermo Scientific Stellar Mass Spectrometer to extend its leadership in proteomics. In the bioproduction business, the company launched a first-of-its-kind bio-based film for single-use technologies. Within the laboratory products business, Thermo Fisher launched a new line of Energy Star-certified Thermo Scientific TSX universal series ULT freezers. The company\u2019s spree of innovation and portfolio strengthening process requires a major thrust on R&D. In recent years, Thermo Fisher has gradually ramped up its investment in R&D. Zacks Investment Research Image Source: Zacks Investment Research Advancing Collaborations and Partnerships: A key pillar of Thermo Fisher\u2019s growth strategy is the trusted partner status it has built with customers, which allows the company to understand their unmet needs early and bring differentiated products, services and expertise. In lieu of this, during the third quarter, the company expanded its pharma services manufacturing footprint in Cincinnati, OH, and Bend, OR. Within the clinical research business, Thermo Fisher expanded its global laboratory services network with a new bioanalytical lab in Gothenburg, Sweden, to support pharmaceutical and biotech customers with advanced laboratory services. Story Continues Additionally, earlier this year, the company collaborated with Bayer to develop a next-generation sequencing-based companion diagnostic. Also, within the analytical instruments business, it partnered with the North Carolina Collaboratory to support PFAS research capacity. Thermo Fisher improved its supply chain in Asia-Pacific by optimizing inventory across its network. While in Europe, the company streamlined and automated its manufacturing processes for high-end analytical instruments to meet strong demand. Strategic Acquisitions to Boost Growth: Thermo Fisher\u2019s business strategy primarily includes expansion through the strategic acquisition of technologies and businesses that augment the company\u2019s existing products and services. A few of its recent strategic acquisitions that are likely to drive future growth include the $3.1 billion acquisition of Olink Holdings. The acquisition, closed in the third quarter, is strategically enhancing Thermo Fisher\u2019s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. Through acquisitions, the company expects to deliver $125 million in adjusted operating income synergies in year five, driven by revenue synergies and cost efficiencies. Among the significant acquisitions of 2023, the CorEvitas buyout advanced Thermo Fisher\u2019s clinical research capabilities with a leading regulatory-grade registry platform. Meanwhile, the acquisition of MarqMetrix has added highly complementary Raman-based in-line PAT to the company\u2019s portfolio. Concerns for Thermo Fisher Macroeconomic Challenges Continue to Weigh on the Stock: The industry-wide trend of difficult macroeconomic conditions in the form of geopolitical pressure leading to disruptions in economic activity, global supply chains and labor markets is creating a challenging business environment for Thermo Fisher. Volatile financial market dynamics and significant volatility in the price and availability of goods and services are putting pressure on the company\u2019s profitability. With sustained macroeconomic pressures, TMO may struggle to keep its operating expenses in check. Tough Competitive Pressure: Due to its diversified portfolio, Thermo Fisher faces different types of competitors, including a broad range of manufacturers and third-party distributors. The competitive landscape is quite tough with changing technology and customer demands that require continuing research and development. TMO Stock Estimate Trend The Zacks Consensus Estimate for the company\u2019s 2024 earnings per share (EPS) has moved up 1 cent to $21.69 in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2024 revenues is pegged at $42.73 billion. This suggests a 0.3% drop from the year-ago reported number. Key MedTech Stocks Some better-ranked stocks in the broader medical space are Veracyte VCYT, Phibro Animal Health PAHC and Haemonetics HAE. Veracyte has an estimated 2024 earnings growth rate of 37.2% compared with the industry\u2019s 15.3%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 520.6%. Its shares have surged 70.3% compared with the industry\u2019s 12.5% growth in the past year. VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Phibro Animal Health, sporting a Zacks Rank #1 at present, has an estimated earnings growth rate of 35.3% for fiscal 2025 compared with the industry\u2019s 11.1%. Shares of the company have surged 99.1% compared with the industry\u2019s 16.6% growth over the past year. PAHC\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. Haemonetics, carrying a Zacks Rank #2 (Buy) at present, has an estimated fiscal 2025 earnings growth rate of 15.9% compared with the industry\u2019s 12.3%. Shares of the company have declined 10.9% against the industry\u2019s 16.6% growth. HAE\u2019s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 2.82%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-24T13:08:00+00:00", "sentiment": {"score": 0.8381846388801932, "confidence": 0.8464499711990356, "probabilities": {"positive": 0.8464499711990356, "negative": 0.008265332318842411, "neutral": 0.1452847123146057}}, "embedding": [-0.20716243982315063, -0.1425541788339615, -0.12448149919509888, -0.042179979383945465, -0.009228890761733055, -0.034854575991630554, -0.08606710284948349, 0.19949832558631897, 0.02142000012099743, 0.05000021308660507, -0.04302569851279259, 0.02131544053554535, -0.04775658994913101, 0.045842114835977554, -0.047802332788705826, -0.014950063079595566, 0.07731674611568451, -0.028356151655316353, -0.07396701723337173, 0.026556864380836487, 0.013116475194692612, -0.04472394660115242, 0.0756555125117302, 0.009130804799497128, 0.0029932409524917603, 0.01367921382188797, -0.04427479952573776, 0.05406488478183746, -0.18189434707164764, 0.0509263351559639, -0.12821613252162933, 0.15744225680828094, 0.11058755218982697, -0.05420469120144844, -0.028847133740782738, 0.04312693327665329, -0.06524547189474106, 0.02039438858628273, 0.01809452846646309, -0.0027337688952684402, 0.020317278802394867, -0.09636937081813812, -0.025689564645290375, -0.004884316585958004, -0.025168074294924736, -0.07077616453170776, 0.09695408493280411, -0.017560003325343132, 0.09727135300636292, -0.009220954962074757, -0.21797659993171692, -0.13114148378372192, 0.07794123888015747, -0.029301956295967102, -0.1116073727607727, 0.09456366300582886, -0.038651905953884125, -0.18051153421401978, -0.00771344406530261, -0.05809760466217995, 0.03340388089418411, -0.0543973445892334, -0.006463838275521994, 0.13723954558372498, 0.17197942733764648, -0.01992149092257023, 0.010551489889621735, 0.03117765486240387, -0.07211347669363022, -0.03183574974536896, 0.09312508255243301, -0.04006374627351761, 0.045548196882009506, 0.07623189687728882, -0.08065443485975266, 0.1399078071117401, 0.20432525873184204, -0.0057169655337929726, 0.280925452709198, -0.020427610725164413, 0.11418090015649796, -0.12671171128749847, 0.023825883865356445, -0.028050806373357773, -0.13605552911758423, 0.0787445679306984, 0.09182357043027878, 0.10866931080818176, 0.09999904781579971, 0.041697435081005096, 0.032657887786626816, -0.0676584392786026, -0.04630253091454506, -0.06146920844912529, -0.08440592885017395, 0.03700236231088638, -0.07909449934959412, 0.008395159617066383, 0.048077329993247986, -0.05243517830967903, -0.015710312873125076, 0.015359928831458092, -0.00894092209637165, -0.06608924269676208, 0.00813678652048111, -0.07440308481454849, 0.027920512482523918, -0.07794192433357239, 0.2072431445121765, 0.0628863126039505, -0.1341109573841095, 0.11542202532291412, -0.08998064696788788, 0.03272309899330139, -0.043963104486465454, 0.013614911586046219, -0.056037407368421555, 0.0495159775018692, 0.11358897387981415, 0.12148624658584595, 0.07389263063669205, 0.061986323446035385, 0.01938026025891304, 0.007654119748622179, -0.02193531207740307, 0.03095199353992939, -0.08439670503139496, 8.589284324212668e-33, -0.0657053291797638, 0.13487012684345245, 0.03231149911880493, 0.045679643750190735, 0.018696404993534088, 0.014739970676600933, -0.02799263969063759, 0.049764469265937805, -0.1332070231437683, -0.08338731527328491, -0.10984566807746887, 0.13142922520637512, -0.07407278567552567, 0.07032977789640427, -0.06307799369096756, -0.011889468878507614, -0.07647565752267838, 0.027799632400274277, 0.025850830599665642, -0.10074819624423981, -0.0458851121366024, 0.0029780943877995014, 0.04795301705598831, 0.11989153921604156, 0.07527440041303635, 0.0978691577911377, -0.01609201729297638, 0.025174900889396667, -0.06910370290279388, 0.09026937186717987, -0.006497847847640514, 0.007424383889883757, -0.11011217534542084, -0.15667226910591125, 0.03523053973913193, -0.09265486150979996, -0.11940424144268036, -0.09793935716152191, 0.0857996940612793, 0.08236022293567657, -0.0763711929321289, 0.12986397743225098, -0.1577804982662201, 0.008063149638473988, -0.06149042397737503, -0.0403192862868309, -0.030672617256641388, 0.03884553909301758, 0.05880801007151604, 0.0011196532286703587, -0.1337783932685852, -0.017304420471191406, -0.010794324800372124, -0.10546058416366577, -0.04876326397061348, -0.03952736780047417, -0.06337521225214005, -0.08758008480072021, 0.05936570093035698, 0.0637412890791893, -0.10168437659740448, 0.13218015432357788, -0.06519439071416855, 0.01077254582196474, -0.0563967190682888, 0.22846902906894684, 0.03964473679661751, -0.043369110673666, -0.04928327351808548, 0.0627729669213295, -0.008172448724508286, -0.10018455982208252, 0.11325166374444962, -0.157180055975914, 0.05724281072616577, -0.005536005832254887, -0.0126389991492033, 0.01388663612306118, 0.017190303653478622, -0.033555783331394196, 0.01918713003396988, 0.026150714606046677, 0.06548751890659332, 0.048556409776210785, -0.028576504439115524, -0.11595359444618225, -0.053620025515556335, 0.025628160685300827, -0.013850556686520576, -0.02375810034573078, 0.056803829967975616, -0.10289697349071503, -0.026019170880317688, 0.09690891206264496, 0.07766003906726837, -8.740103922843014e-33, -0.1271720826625824, -0.02047225646674633, 0.01236119493842125, 0.003373086219653487, 0.004109825007617474, -0.07495088130235672, 0.0450141616165638, -0.007285986095666885, 0.05185660347342491, -0.12924164533615112, 0.008507889695465565, 0.08614982664585114, -0.08662603050470352, -0.0801001638174057, -0.04335235804319382, 0.06988120079040527, -0.08194682747125626, -0.05885929614305496, -0.0365125872194767, -0.14280736446380615, 0.14853328466415405, 0.10275419056415558, -0.08998929709196091, 0.1148105338215828, 0.023308593779802322, 0.06894603371620178, -0.060120634734630585, 0.014262441545724869, 0.11574316024780273, -0.03965644910931587, -0.007350443862378597, -0.015481386333703995, -0.08321598172187805, 0.0721968561410904, -0.019084688276052475, 0.022713737562298775, 0.11784026771783829, -0.08369864523410797, 0.06174847483634949, -0.05099065229296684, 0.22022774815559387, -0.038642555475234985, 0.01835947483778, -0.09888936579227448, 0.004883849062025547, 0.02229500561952591, 0.06145896390080452, -0.10086126625537872, 0.17738327383995056, 0.10060709714889526, 0.028315821662545204, -0.016851505264639854, -0.07500863820314407, 0.015400645323097706, -0.017668195068836212, -0.01655503176152706, 0.02826356329023838, 0.012061160057783127, -0.1322234719991684, -0.05770770460367203, 0.03461460396647453, 0.03686613216996193, 0.03164806216955185, 0.06425018608570099, -0.016897378489375114, 0.0996694415807724, 0.11122036725282669, -0.02474840171635151, 0.01995122991502285, -0.10636346787214279, 0.0008427927969023585, 0.006011242046952248, 0.07355567812919617, -0.20269334316253662, -0.06046873331069946, 0.14112111926078796, -0.017871543765068054, -0.1367936134338379, -0.041441660374403, -0.009188495576381683, -0.06874587386846542, -0.02570032700896263, 0.06404685974121094, 0.0695168524980545, 0.10005025565624237, 0.11596447974443436, 0.09731508046388626, -0.03254569321870804, -0.11886480450630188, -0.05791748687624931, -0.09379878640174866, -0.05656508356332779, -0.055960673838853836, 0.07124190777540207, 0.06566044688224792, -1.0026293750797777e-07, 0.0999891459941864, -0.07515549659729004, 0.1275789588689804, -0.04869116097688675, 0.13440796732902527, -0.06270291656255722, -0.03929572552442551, 0.11824827641248703, 0.1431315839290619, 0.17730191349983215, 0.06455652415752411, 0.11928713321685791, -0.043358735740184784, 0.07075625658035278, -0.02428119257092476, -0.04986442252993584, -0.0956936627626419, 0.021557368338108063, -0.10883750021457672, -0.09658338129520416, -0.04344014450907707, 0.012485058978199959, 0.10692153871059418, -0.08455643057823181, 0.043395593762397766, -0.037671178579330444, -0.10791383683681488, -0.011736374348402023, 0.061147019267082214, -0.01946452632546425, -0.0620247982442379, -0.05260751396417618, 0.04685869812965393, 0.10577377676963806, 0.09357869625091553, -0.08532480150461197, 0.00980282574892044, 0.06417100131511688, 0.024726390838623047, 0.12077528238296509, 0.00656014122068882, 0.02976391278207302, -0.05556904524564743, 0.10864848643541336, 0.027330080047249794, 0.009337151423096657, -0.1516888439655304, 0.021425209939479828, 0.035127896815538406, -0.039705485105514526, 0.047264665365219116, -0.024264780804514885, -0.1462605595588684, 0.000870339572429657, -0.09852981567382812, 0.08435094356536865, -0.05068851634860039, -0.051131587475538254, -0.0683128833770752, 0.04476657882332802, 0.11845853179693222, -0.31532785296440125, 0.023740049451589584, 0.07950904965400696], "changes": {"1wk": -1.906239028436139}}, {"text": "Mixed results for Keytruda; AbbVie to work with Neomorph BioPharma Dive \u00b7 Daniel Tadevosyan via Getty Images BioPharma Dive staff Fri, Jan 24, 2025, 2:17 PM 2 min read In This Article: ABBV +3.39% AZN -1.27% VIGL +4.20% MRK +0.98% This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter . Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. A regimen of cancer drugs Keytruda and Lenvima extended progression-free survival over standard chemotherapy in people with a type of gastroesophageal tumor, but did not show an overall survival benefit. The results, announced by Merck & Co. and Eisai Friday , are from a Phase 3 study called LEAP-015 that enrolled hundreds of people with locally advanced unresectable or metastatic HER2-negative gastroesophageal adenocarcinoma. The companies said they are continuing to evaluate the data, which they\u2019ll present at a future medical meeting. The findings do not affect Keytruda or Lenvima\u2019s current approvals, or other trials in the LEAP program. \u2014 Ned Pagliarulo AstraZeneca will invest $570 million in a new office facility in Ontario that will help grow the company\u2019s presence in Canada. The drugmaker already employs more than 2,100 people in Canada \u2014 many of whom work on clinical trials \u2014 and last year acquired Hamilton, Ontario-based Fusion Pharmaceuticals . The new facility will add more than 700 positions to its workforce there, across \u201call areas of the business,\u201d AstraZeneca said Thursday. \u2014 Ben Fidler AbbVie will work with San Diego-based biotech startup Neomorph to develop protein-degrading \u201cmolecular glue\u201d drugs for cancer and immune diseases, the companies announced Thursday. Neomorph will get an unspecified upfront payment from AbbVie in the deal and stands to receive up to $1.64 billion more in option fees and milestones. It\u2019s the third industry collaboration since last February for Neomorph, which also has partnerships with Biogen and Novo Nordisk . \u2014 Ben Fidler The Food and Drug Administration will take another three months to decide whether it will approve Stealth BioTherapeutics \u2019 drug elamipretide for Barth syndrome. The company on Thursday said the FDA determined it needs more time to review recent information submitted by Stealth following an October meeting of agency advisers. The FDA didn\u2019t cite any safety issues, nor did it request more testing, Stealth said. The new decision deadline is April 29. \u2014 Ned Pagliarulo Shares in Vigil Neuroscience rose by double digits this week after the biotechnology company reported Phase 1 trial data for an experimental drug it\u2019s developing for Alzheimer\u2019s. The data, which detail the drug\u2019s safety and distribution through the body, support advancement into a Phase 2 study, Vigil said. Code-named VG-3927 , the small molecule drug is designed to boost a neuroprotective response in the brain to accumulations of tau and amyloid, proteins associated with Alzheimer\u2019s. \u2014 Ned Pagliarulo Story Continues Recommended Reading Intellia makes progress on HAE study; 2 more China drug deals View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-24T11:17:07+00:00", "sentiment": {"score": 0.27823490276932716, "confidence": 0.2884748876094818, "probabilities": {"positive": 0.2884748876094818, "negative": 0.010239984840154648, "neutral": 0.7012851238250732}}, "embedding": [0.02057499624788761, -0.11640366911888123, -0.11597169935703278, -0.07647190988063812, -0.040895890444517136, -0.11486944556236267, -0.050850480794906616, 0.23135867714881897, 0.0675002932548523, -0.01093389093875885, -0.08257083594799042, 0.10255289077758789, 0.06546314060688019, -0.005144491326063871, -0.038805048912763596, 0.10433058440685272, 0.08589449524879456, -0.05394821614027023, -0.07099558413028717, 0.12859511375427246, 0.0233706533908844, -0.04592178761959076, 0.1174004077911377, 0.03178942948579788, -0.0009200787171721458, 0.032135844230651855, -0.06001339852809906, -0.037394605576992035, -0.17802996933460236, -0.047268204391002655, 0.04735652357339859, 0.04294721782207489, -0.024129528552293777, -0.043158844113349915, 0.12279658019542694, 0.022354844957590103, -0.11232584714889526, 0.09515612572431564, -0.1477361023426056, -0.058097414672374725, -0.05059724301099777, -0.06621389091014862, -0.12383713573217392, 0.03430283069610596, 0.045465320348739624, -0.18547239899635315, -0.16853547096252441, 0.04237686097621918, 0.022753778845071793, 0.1484897881746292, -0.14033494889736176, -0.1801866888999939, -0.029700657352805138, 0.08668030798435211, -0.037291254848241806, -0.027608491480350494, -0.1377473771572113, -0.029802998527884483, 0.015393096953630447, -0.005133476108312607, 0.07560111582279205, -0.02364734187722206, -0.0031889043748378754, -0.012622296810150146, 0.11477858573198318, 0.004062569234520197, 0.059915363788604736, -0.14394250512123108, -0.035211894661188126, 0.015885721892118454, 0.04216143116354942, -0.09900296479463577, 0.027632426470518112, 0.12297555804252625, -0.08493560552597046, 0.06450015306472778, 0.0792914479970932, 0.05990133434534073, 0.09364888072013855, -0.05246306210756302, 0.17552229762077332, 0.03762250393629074, 0.08641462028026581, 0.01187317818403244, 0.001749243587255478, 0.06878535449504852, 0.009817843325436115, 0.14710134267807007, 0.02707061916589737, -0.0039409855380654335, 0.09315161406993866, -0.009254271164536476, 0.052061423659324646, 0.006324486806988716, 0.03483939915895462, -0.11472193896770477, -0.03497740998864174, -0.0045263320207595825, 0.012028910219669342, -0.04877963289618492, -0.022596675902605057, -0.0633908286690712, -0.10405117273330688, -0.15213018655776978, -0.02830830216407776, -0.0486028715968132, 0.05576672777533531, -0.02000298909842968, 0.08880128711462021, 0.04288231581449509, -0.07742071151733398, 0.08461250364780426, 0.02445237524807453, 0.005787791684269905, -0.05016718804836273, 0.30534887313842773, -0.0134420245885849, 0.04362078011035919, 0.103416308760643, 0.015524032525718212, -0.008263679221272469, 0.03778180107474327, 0.020707271993160248, -0.04106946662068367, 0.08025814592838287, 0.03395937383174896, -0.17587986588478088, 1.4265345406886276e-32, 0.034355729818344116, 0.03798801079392433, 0.10059690475463867, 0.027626290917396545, 0.017356932163238525, 0.05919875577092171, 0.06522925198078156, -0.07196854799985886, -0.10239017009735107, -0.09262306243181229, -0.15978020429611206, -0.024231303483247757, 0.06046261638402939, 0.08586268126964569, -0.12430203706026077, -0.06200084462761879, -0.05297820270061493, 0.06629405915737152, -0.16622620820999146, -0.010471480898559093, 0.040596406906843185, 0.06524110585451126, -0.039462096989154816, 0.07690025120973587, -0.10319256782531738, 0.10558395087718964, -0.18192610144615173, 0.09831901639699936, 0.05412755161523819, 0.034550782293081284, -0.1793365478515625, 0.07083584368228912, -0.028985681012272835, -0.029529552906751633, -0.010357418097555637, -0.053082458674907684, -0.05164138227701187, -0.14466717839241028, 0.010795732960104942, 0.09275159984827042, -0.091737300157547, 0.07406306266784668, -0.0977272018790245, -0.11360204219818115, 0.015613608993589878, -0.12492161989212036, -0.007080947980284691, 0.09062016010284424, -0.051335446536540985, -0.009517014026641846, -0.04655176401138306, 0.015446173027157784, -0.0956871435046196, 0.0023265834897756577, -0.053263068199157715, 0.052724506705999374, -0.08795689046382904, -0.01807020977139473, 0.17797353863716125, 0.0605037622153759, 0.093653604388237, 0.06857644021511078, 0.03398829698562622, 0.033156510442495346, -0.08339093625545502, 0.09878575801849365, -0.024095110595226288, -0.04872538149356842, -0.029091298580169678, 0.12898214161396027, -0.023323485627770424, -0.0006722980178892612, 0.0843978077173233, 0.08030661940574646, 0.06890679895877838, -0.08624657243490219, 0.015991870313882828, 0.07744695246219635, 0.008234597742557526, 0.08354119211435318, 0.0795031487941742, -0.035213444381952286, -0.02756393328309059, 0.05536230280995369, -0.005543690174818039, 0.00013064430095255375, 0.02005796507000923, -0.06020311266183853, -0.14323651790618896, -0.005479076411575079, 0.04344674199819565, -0.1259259134531021, -0.059396084398031235, 0.03150241822004318, 0.03124001994729042, -1.4165952951420436e-32, -0.040389783680438995, 0.0069929445162415504, 0.029679257422685623, -0.07604150474071503, 0.04814496263861656, 0.14469844102859497, -0.007092504296451807, -0.14118361473083496, 0.08622365444898605, -0.131178081035614, -0.005057020112872124, 0.13030807673931122, 0.07402154803276062, -0.023920048028230667, -0.06291355192661285, 0.04583270102739334, 0.014512992464005947, -0.149809330701828, -0.07729049026966095, -0.011646940372884274, -0.003941694274544716, 0.10863596946001053, -0.17843420803546906, 0.08759510517120361, -0.05190516635775566, 0.061487823724746704, 0.06284892559051514, 0.045342445373535156, 0.07171975076198578, -0.06725835055112839, -0.03687301650643349, 0.13928937911987305, -0.25607600808143616, 0.0008348310366272926, -0.022864295169711113, 0.006022010929882526, -0.059557393193244934, -0.1532941609621048, 0.013706877827644348, -0.1336018443107605, 0.0055847689509391785, 0.018643639981746674, -0.057521283626556396, -0.017340226098895073, 0.06488300859928131, 0.020189188420772552, 0.08667352795600891, -0.10563585162162781, 0.142371267080307, -0.038731932640075684, 0.017135847359895706, 0.04920317977666855, -0.026377970352768898, 0.0423910990357399, -0.00024188682436943054, -0.01678469404578209, 0.00196852907538414, -0.03067087009549141, -0.0895603746175766, 0.028776034712791443, -0.0286630317568779, 0.06167478859424591, 0.04459322243928909, 0.0216273944824934, 0.10674808919429779, 0.17245164513587952, 0.1237686425447464, -0.04053744673728943, 0.06561122834682465, -0.08904585242271423, -0.037870459258556366, -0.07177142798900604, -0.006576899439096451, -0.040715932846069336, 0.018820729106664658, 0.11657403409481049, -0.009784028865396976, -0.06310614198446274, -0.11865557730197906, -0.03665010631084442, 0.02236686833202839, -0.11484372615814209, 0.08633174747228622, -0.022529110312461853, 0.05518225580453873, 0.14568260312080383, -0.04789375513792038, -0.07000461220741272, -0.08307964354753494, 0.05100849270820618, -0.0703621655702591, -0.09084960073232651, -0.0746283009648323, 0.08576475083827972, 0.053351160138845444, -1.006042680273822e-07, 0.12987959384918213, 0.021238388493657112, -0.02382407896220684, -0.09271988272666931, 0.031391583383083344, -0.046898581087589264, -0.08833297342061996, 0.13677319884300232, -0.014881229028105736, 0.10727810859680176, 0.02639615535736084, 0.09528768807649612, -0.035432323813438416, -0.022187985479831696, -0.022217566147446632, 0.0991310402750969, 0.013873588293790817, 0.01351894624531269, -0.004777953028678894, 0.03209412842988968, -0.15646065771579742, -0.013793602585792542, 0.024892544373869896, -0.08464496582746506, 0.041386865079402924, -0.0023501720279455185, 0.057131942361593246, 0.10052302479743958, 0.06763158738613129, -0.050571948289871216, -0.026337865740060806, -0.03777717053890228, 0.06695783138275146, 0.016347886994481087, -0.09061276912689209, -0.14594563841819763, 0.06475196778774261, 0.09140998125076294, 0.03269319236278534, 0.1854265183210373, 0.10981477051973343, 0.015174370259046555, -0.018390128389000893, 0.029062721878290176, -0.08327437937259674, 0.008444879204034805, -0.08675752580165863, -0.0875890702009201, -0.004864431917667389, -0.08318974077701569, 0.0365474559366703, -0.03700760379433632, -0.032627929002046585, -0.007575737312436104, 0.025500014424324036, 0.12175693362951279, -0.09802945703268051, -0.027218246832489967, 0.05371681600809097, -0.016950203105807304, -0.016411511227488518, -0.18923503160476685, 0.10149956494569778, 0.03969946503639221], "changes": {"1wk": -1.906239028436139}}, {"text": "Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema Intellia aims to submit a biologics license application in 2026. Credit: Piotr Swat/Shutterstock. \u00b7 Clinical Trials Arena \u00b7 Piotr Swat/Shutterstock. GlobalData Thu, Jan 23, 2025, 5:14 PM 2 min read In This Article: NTLA -7.56% Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema (HAE). HAELO is a double-blind trial that will assess the therapy\u2019s safety and efficacy in 60 adult subjects with Type I or Type II HAE. Subjects will be randomised to receive either one 50 mg infusion of the therapy or a placebo. Those in the placebo group will have the option to cross over to the therapy treatment at a 28-week time period. The trial's key endpoints will measure the count of HAE attacks and the proportion of subjects achieving attack-free status between week five and week 28. Intellia Therapeutics CEO and president John Leonard said: \u201cWe are pleased to have initiated dosing in the HAELO Phase III study as we are in our final lap of clinical development for NTLA-2002. With the promising data we\u2019ve presented thus far, we believe patients could achieve independence from both HAE attacks and medications required to treat this disease. \u201cWe look forward to presenting longer-term data from the ongoing Phase I/II study later this year highlighting the durability of the effect of NTLA-2002.\u201d Subject enrolment is anticipated to be completed by the second half of this year and the company aims to submit a biologics license application (BLA) in 2026. The therapy launch in the US market is expected in 2027. Leveraging CRISPR/Cas9 technology, NTLA-2002 aims to target the kallikrein B1 (KLKB1) gene to eliminate attacks. NTLA-2002 has received several regulatory designations, including the Food and Drug Administration\u2019s (FDA) orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designation, and the UK Medicines and Healthcare Products Regulatory Agency\u2019s (MHRA) Innovation Passport. It also secured the European Medicines Agency (EMA)\u2019s PRIME designation, and orphan drug status from the European Commission (EC). In October last year, the company reported positive outcomes from its ongoing Phase I/II trial of NTLA-2002 for HAE. \"Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View comments Terms and Privacy Policy Privacy Dashboard Recommended stories", "symbol": "HAE", "date": "2025-01-23T14:14:06+00:00", "sentiment": {"score": 0.5738394148647785, "confidence": 0.5832103490829468, "probabilities": {"positive": 0.5832103490829468, "negative": 0.009370934218168259, "neutral": 0.40741869807243347}}, "embedding": [-0.056937817484140396, -0.08782635629177094, 0.005491018760949373, -0.02797912433743477, -0.08083591610193253, -0.11208874732255936, -0.08835573494434357, 0.17485928535461426, 0.06704246997833252, 0.028457369655370712, -0.08255695551633835, 0.07118310034275055, -0.006976202130317688, -0.019533811137080193, -0.0653565526008606, 0.07471048831939697, -0.05661611258983612, -0.052334219217300415, -0.09751985967159271, 0.08226178586483002, -0.0070317573845386505, 0.037980176508426666, 0.05408124998211861, 0.030903393402695656, -0.11017704755067825, -0.013548064045608044, 0.031938839703798294, -0.058166518807411194, -0.10231174528598785, -0.08402296900749207, 0.07674131542444229, 0.05971413850784302, -0.008336084894835949, -0.11543656885623932, 0.030941102653741837, -0.09290596842765808, -0.17886947095394135, 0.029907546937465668, -0.058318428695201874, -0.03661379963159561, 0.050880737602710724, -0.173648864030838, -0.09418812394142151, 0.007467522285878658, 0.027670621871948242, -0.09168295562267303, -0.025246841832995415, 0.023066150024533272, -0.06770141422748566, 0.26288294792175293, -0.2163034975528717, -0.17862668633460999, -0.0947832316160202, 0.12145107984542847, -0.04252110421657562, -0.12188008427619934, -0.1859895884990692, -0.0009562664199620485, 0.06310975551605225, 0.08112110197544098, -0.04894739389419556, -0.060431160032749176, -0.06479555368423462, -0.03192269429564476, -0.021930072456598282, 0.013236469589173794, 0.1074960008263588, -0.11945284157991409, 0.07186292111873627, -0.03725409135222435, 0.1760583519935608, -0.04245751351118088, -0.030699970200657845, 0.09434692561626434, -0.08023824542760849, 0.10329967737197876, 0.11779996752738953, 0.08857771754264832, 0.16791576147079468, -0.11331261694431305, 0.036914460361003876, 0.041286926716566086, 0.057671234011650085, -0.02197357639670372, 0.04771317541599274, 0.08425067365169525, -0.0006144717335700989, 0.19552165269851685, 0.0328398272395134, -0.005130920093506575, 0.13565629720687866, 0.057496629655361176, 0.006915612146258354, 0.04344217851758003, 0.05306762456893921, -0.04009518772363663, -0.004047921858727932, 0.02769809029996395, -0.0357186496257782, 0.06409058719873428, 0.06678123027086258, -0.04446396231651306, -0.0672631710767746, 0.0257253497838974, -0.07030604779720306, -0.01488729938864708, 0.016056576743721962, -0.17691746354103088, -0.03195900470018387, -0.027253437787294388, -0.027615655213594437, 0.00920029729604721, 0.06953912228345871, -0.025065479800105095, -0.06153101474046707, 0.12623071670532227, -0.023137472569942474, 0.031662467867136, 0.1946311891078949, -0.012091622687876225, 0.10043197870254517, -0.08233779668807983, 0.07504165172576904, -0.15072530508041382, 0.11035093665122986, 0.048578981310129166, -0.10727088898420334, 9.170143102727993e-33, 0.02620106190443039, -0.06167742609977722, -0.0064120907336473465, 0.0673389658331871, -0.07250887900590897, -0.07965259999036789, 0.039003193378448486, -0.04270145297050476, -0.20604100823402405, -0.06762747466564178, -0.07055427134037018, -0.1021077036857605, 0.03097866103053093, 0.10367536544799805, -0.08799213171005249, -0.04064520448446274, 0.04200594499707222, 0.11135537922382355, -0.0593748539686203, 0.0899931862950325, 0.039876099675893784, -0.03203112259507179, -0.08710145950317383, 0.04230104386806488, -0.0994165763258934, 0.13722674548625946, 0.008901052176952362, 0.009816968813538551, 0.032502949237823486, 0.10394060611724854, -0.07790723443031311, -0.04626813530921936, 0.039736345410346985, -0.08287878334522247, -0.07247921824455261, -0.04170580208301544, -0.01053284015506506, -0.031898580491542816, -0.03434547781944275, 0.16883942484855652, 0.041959717869758606, 0.15285013616085052, -0.13020196557044983, -0.0615260973572731, 0.11040391027927399, -0.21841469407081604, -0.038262639194726944, 0.030186109244823456, -0.03556433320045471, 0.024771029129624367, -0.043992843478918076, -0.10295374691486359, 0.044878292828798294, 0.025166422128677368, 0.011916287243366241, 0.06452655792236328, -0.17295695841312408, 0.02667931094765663, 0.12444211542606354, 0.06255760043859482, 0.06132407486438751, 0.02388249896466732, -0.011089418083429337, 0.11350856721401215, -0.04222937673330307, 0.06115962192416191, -0.06545983254909515, -0.07809878885746002, -0.041115790605545044, 0.028766915202140808, 0.03551061823964119, -0.07147975265979767, 0.10680711269378662, -0.0035517620854079723, -0.08019397407770157, -0.11872053146362305, 0.11025067418813705, 0.2038041055202484, -0.012423895299434662, 0.033644869923591614, 0.05717303976416588, 0.023826997727155685, -0.07088058441877365, 0.11517345905303955, -0.06559066474437714, -0.11795957386493683, 0.05221298709511757, -0.04835347831249237, -0.251625120639801, -0.05504930764436722, 0.1628408432006836, -0.03514585271477699, -0.03381083160638809, 0.040939293801784515, 0.04193269833922386, -1.0730578057981993e-32, -0.010069265961647034, -0.008890682831406593, -0.09247863292694092, -0.04743954539299011, -0.03160368278622627, 0.10131935030221939, 0.08540947735309601, -0.04567583650350571, 0.15715868771076202, -0.11070746928453445, 0.07221347838640213, 0.06104213371872902, -0.011719336733222008, -0.05792874097824097, -0.04480142891407013, 0.0042487639002501965, -0.029616234824061394, -0.09851524233818054, -0.06863027811050415, 0.07125833630561829, 0.04551441967487335, 0.10556790232658386, -0.043547388166189194, 0.02916407585144043, 0.007909270003437996, 0.01905655674636364, -0.05367066711187363, 0.07206280529499054, 0.026755761355161667, -0.014812611043453217, -0.06330647319555283, -0.033613648265600204, -0.20211240649223328, -0.03863372281193733, -0.03855406120419502, -0.05170155689120293, 0.17755398154258728, -0.12068495154380798, 0.03873289376497269, -0.014788106083869934, 0.09367306530475616, 0.05367936193943024, -0.03522187098860741, 0.043010272085666656, 0.033248551189899445, 0.10505180060863495, 0.09054768085479736, 0.007272320333868265, 0.14072838425636292, -0.08884499967098236, 0.009373427368700504, 0.057583414018154144, -0.009889842011034489, 0.046670593321323395, 0.008576684631407261, -0.1332181692123413, 0.12985628843307495, -0.08915377408266068, -0.1725699007511139, 0.05173029378056526, 0.006815444678068161, -0.04273449629545212, 0.02657219022512436, 0.019456125795841217, 0.06301788985729218, 0.18815287947654724, 0.0269274041056633, 0.008182956837117672, -0.013672665692865849, -0.07571788132190704, -0.12351517379283905, -0.03907245025038719, -0.058480799198150635, -0.13003969192504883, 0.1035168319940567, 0.02087824046611786, -0.044589295983314514, -0.039800938218832016, -0.08494295179843903, -0.047329410910606384, -0.06762294471263885, -0.14202839136123657, -0.07671435177326202, -0.0785035789012909, 0.037313684821128845, -0.00961989164352417, 0.04911995679140091, -0.07754189521074295, 0.04445155709981918, -0.012255920097231865, -0.14457693696022034, -0.11649594455957413, -0.09253838658332825, 0.08804154396057129, -0.07732763141393661, -1.0155996932326161e-07, 0.1991155743598938, -0.04969972372055054, -0.11092200875282288, -0.042612332850694656, -0.040250830352306366, -0.048297856003046036, -0.14544105529785156, 0.05813830345869064, 0.012115414254367352, 0.08741147816181183, 0.144926056265831, 0.15820449590682983, -0.01755402609705925, -0.06520687788724899, 0.07629328966140747, 0.03226206824183464, 0.06336547434329987, -0.0002286648377776146, -0.057099372148513794, -0.04397207126021385, 0.00500066950917244, 0.029443785548210144, 0.1550588309764862, -0.16022908687591553, 0.07648816704750061, -0.023938573896884918, 0.05048021674156189, 0.02277662791311741, -0.04293888434767723, -0.06736806780099869, -0.010433959774672985, -0.04685916379094124, 0.08330349624156952, 0.05807529389858246, -0.040849678218364716, -0.1038193628191948, 0.11154049634933472, 0.16577765345573425, 0.06865651905536652, 0.16101428866386414, 0.016054613515734673, 0.008804494515061378, -0.09782147407531738, -0.0024165958166122437, 0.02453991211950779, 0.022820133715867996, -0.07156698405742645, -0.06834806501865387, 0.05972306802868843, -0.11005702614784241, -0.16975292563438416, 0.06547293066978455, -0.0140704195946455, -0.05925295501947403, 0.02386334538459778, 0.20974978804588318, -0.0037255026400089264, 0.010089089162647724, 0.02049645222723484, -0.04810896888375282, 0.1314907819032669, 0.04331028461456299, 0.014954004436731339, -0.021371476352214813], "changes": {"1wk": -6.272302575543676}}, {"text": "NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate Zacks Equity Research Thu, Jan 23, 2025, 4:56 PM 3 min read In This Article: NTLA -7.56% Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR\u00a0gene editing therapy for the treatment of hereditary angioedema (HAE). Shares of the company were up 10.8% on Jan. 22 following the announcement of the news. The global double-blind, placebo-controlled HAELO study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The key endpoint of the study is to see the change in the number of HAE attacks from week five through week 28 of treatment. Enrollment of patients in the study is expected to be completed in the second half of 2025. Intellia plans to submit a biologics license application for NTLA-2002 in HAE in 2026. Upon potential approval, the company plans to launch NTLA-2002 in 2027 in the United States. In October 2024, NTLA initiated the HAELO study on NTLA-2002 for treating HAE. Despite the current treatment options that require chronic administration for disease control, HAE attacks still occur. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity. In the past year, shares of Intellia have plunged 56.1% compared with the industry\u2019s decline of 12%. Zacks Investment Research Image Source: Zacks Investment Research NTLA Developing Another Candidate NTLA-2001 Besides NTLA-2002, Intellia is developing its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA-2001). The company has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company\u2019s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. Earlier this month, the company announced a strategic reorganization of its portfolio wherein it prioritized the development of nex-z, which is being studied for two indications, ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR amyloidosis with cardiomyopathy. Enrollment is currently ongoing in the study. The phase III MAGNITUDE 2 study is actively screening patients with hereditary ATTR amyloidosis with polyneuropathy, with the first patient expected to be dosed later in the first quarter of 2025. NTLA's Zacks Rank & Stocks to Consider Intellia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Story Continues In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.58 for 2025. In the past year, shares of VYGR have plunged 27.2%. VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 35.1%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-23T13:56:00+00:00", "sentiment": {"score": 0.7246616538614035, "confidence": 0.7437365651130676, "probabilities": {"positive": 0.7437365651130676, "negative": 0.01907491125166416, "neutral": 0.23718850314617157}}, "embedding": [-0.15013054013252258, -0.09813225269317627, -0.030593818053603172, -0.012429988943040371, -0.14502286911010742, -0.1325640082359314, -0.06381814181804657, 0.16552838683128357, 0.0420897975564003, 0.029493484646081924, -0.056927405297756195, 0.129405215382576, -0.04296603798866272, -0.0020830063149333, -0.09945192188024521, 0.03102681040763855, -0.03442925587296486, -0.04194893687963486, -0.13944485783576965, 0.0709831565618515, -0.026881013065576553, 0.022060584276914597, 0.08625239878892899, -0.04762435704469681, -0.08265712857246399, -0.023729823529720306, 0.04595235735177994, -0.07361339777708054, -0.04540608823299408, -0.08518322557210922, 0.005572113674134016, 0.08863997459411621, 0.009650040417909622, -0.13375085592269897, 0.02673589251935482, -0.09425599128007889, -0.2038976550102234, 0.06965818256139755, -0.10038132965564728, -0.03111111745238304, 0.0353020541369915, -0.14722946286201477, -0.13647985458374023, -0.038875170052051544, -0.008468223735690117, -0.13057482242584229, -0.03173212707042694, -0.01843830570578575, -0.01811818778514862, 0.21384736895561218, -0.25002408027648926, -0.20098145306110382, -0.018384503200650215, 0.09193991124629974, -0.06193316727876663, -0.048141926527023315, -0.1934613287448883, -0.01759922318160534, 0.06765276938676834, 0.060060374438762665, 0.06511528789997101, -0.016249317675828934, -0.08008967339992523, -0.008671378716826439, 0.03288566693663597, 0.026176609098911285, 0.11199915409088135, -0.10530424863100052, 0.0012450646609067917, -0.08822354674339294, 0.18220248818397522, -0.04290653020143509, -0.03658492863178253, 0.0659259632229805, -0.10850796103477478, 0.11416995525360107, 0.1523699015378952, 0.045276060700416565, 0.18907269835472107, -0.13996653258800507, 0.11739308387041092, 0.06430348753929138, 0.10990777611732483, 0.04189653694629669, 0.0577315017580986, 0.17076349258422852, -0.017339356243610382, 0.1683521866798401, 0.08717823773622513, 0.05909190699458122, 0.09471757709980011, 0.06819798052310944, 0.04830775782465935, -0.0365305170416832, 0.024702386930584908, -0.012395298108458519, 0.00966508500277996, 0.027436356991529465, 0.025943176820874214, 0.0809207558631897, 0.06306935846805573, 0.022018611431121826, -0.01976417936384678, -0.015949495136737823, -0.06051898002624512, 0.018147993832826614, 0.06689362972974777, -0.16591331362724304, -0.02703840658068657, 0.021114379167556763, -0.07952232658863068, 0.017405319958925247, 0.004725290462374687, -0.041087597608566284, -0.0753607302904129, 0.11974373459815979, -0.020252645015716553, 0.03096579760313034, 0.13026420772075653, 0.009055312722921371, 0.06930837035179138, -0.09121076762676239, 0.03093973733484745, -0.10510586202144623, 0.2049463391304016, 0.06228918582201004, -0.16819649934768677, 1.0347994319723679e-32, -0.004916494712233543, 0.033124443143606186, -0.056239426136016846, 0.039137449115514755, -0.04298997297883034, -0.057675495743751526, 0.029687877744436264, -0.04180920496582985, -0.174665629863739, -0.1171358972787857, -0.06350481510162354, -0.130898118019104, 0.01297385711222887, 0.06130601838231087, -0.07080742716789246, -0.06514100730419159, 0.044256843626499176, 0.08050084859132767, -0.04072233662009239, 0.06370046734809875, 0.036629341542720795, -0.013856559991836548, -0.06825389713048935, 0.0006246541161090136, -0.12185559421777725, 0.08523876219987869, -0.05354204773902893, 0.03680950403213501, 0.031028788536787033, 0.07637373358011246, -0.031615447252988815, -0.034718357026576996, 0.0034196763299405575, -0.12396641075611115, -0.012434699572622776, 0.03791208937764168, -0.003243083134293556, -0.06214030086994171, -0.02697959542274475, 0.1442662924528122, 0.01821162924170494, 0.18853026628494263, -0.16273203492164612, -0.09150946140289307, 0.10702553391456604, -0.10932574421167374, -0.07073871791362762, 0.029850158840417862, 0.0019036941230297089, -0.01365445926785469, -0.04175884276628494, -0.03298844397068024, 0.006147740408778191, -0.0801733136177063, -0.009484350681304932, 0.04972601681947708, -0.14848557114601135, -0.013287784531712532, 0.17878413200378418, 0.10197755694389343, 0.04849374294281006, 0.02127993479371071, -0.034974854439496994, 0.11122104525566101, -0.053410787135362625, 0.07442671060562134, -0.03238167613744736, -0.11299776285886765, -0.058703258633613586, 0.03796203434467316, 0.005196761339902878, -0.09182554483413696, 0.14539885520935059, -0.013356292620301247, -0.04178909212350845, -0.0976111888885498, 0.033945903182029724, 0.18036136031150818, 0.01875925436615944, 0.012566449120640755, 0.06458432972431183, 0.018977580592036247, -0.02197449840605259, 0.045468367636203766, -0.005098029971122742, -0.1494607925415039, 0.03276137635111809, 0.034175097942352295, -0.16902095079421997, -0.07452628016471863, 0.2393268346786499, -0.031816720962524414, -0.0669219121336937, 0.013346973806619644, 0.04166311025619507, -1.0110076467169156e-32, -0.06667748093605042, 0.018794333562254906, -0.07691611349582672, -0.05613361671566963, -0.05327241122722626, 0.0947941318154335, 0.01909717358648777, -0.02622859925031662, 0.11595054715871811, -0.09809798002243042, 0.1600888967514038, 0.08975479751825333, 0.00793564971536398, -0.04051176458597183, -0.0858817920088768, -0.013597813434898853, -0.0333511158823967, -0.11855946481227875, -0.05004340037703514, -0.0033158492296934128, 0.019276246428489685, 0.12044800072908401, -0.058222584426403046, 0.06793857365846634, 0.030572714284062386, 0.05269426852464676, -0.05082058161497116, 0.14646899700164795, -0.007817856967449188, 0.023319505155086517, -0.09769470989704132, 0.02662820741534233, -0.19965267181396484, -0.04299531877040863, 0.011536972597241402, -0.05870255082845688, 0.12117426097393036, -0.10603468120098114, -0.027764514088630676, -0.10566476732492447, 0.09532549977302551, 0.030189383774995804, 0.03521084785461426, 0.06692421436309814, 0.044644251465797424, 0.12724542617797852, 0.07150360196828842, -0.02626759186387062, 0.13541008532047272, -0.07182830572128296, 0.05615241453051567, 0.05368947237730026, 0.02395769953727722, 0.0461508147418499, 0.055867500603199005, -0.062152884900569916, 0.1735680252313614, -0.06702926009893417, -0.1695130467414856, 0.06052343547344208, -0.009694136679172516, -0.03543795272707939, 0.05541794002056122, 0.003590097650885582, 0.0632619708776474, 0.15969981253147125, 0.03202112019062042, 0.0615079291164875, 0.013308246619999409, -0.0858270674943924, -0.11140000820159912, 0.03850493207573891, -0.016459839418530464, -0.13947710394859314, 0.006598925217986107, 0.0070488471537828445, -0.0223979689180851, -0.0929604321718216, -0.0839974507689476, -0.06415994465351105, -0.09290684759616852, -0.11863511055707932, -0.06473125517368317, -0.05802758038043976, 0.0013045761734247208, 0.04839733988046646, 0.07977943867444992, -0.02921687439084053, -0.042409513145685196, -0.05565936863422394, -0.1526392698287964, -0.11297749727964401, -0.11807094514369965, 0.08271962404251099, -0.04863777756690979, -1.0133656758171128e-07, 0.15529704093933105, -0.10657380521297455, -0.055535636842250824, -0.07303373515605927, 0.03696893900632858, -0.0994957759976387, -0.14615309238433838, 0.10697565972805023, 0.07660283148288727, 0.11635369062423706, 0.08016505837440491, 0.2254607379436493, -0.0015475284308195114, -0.04014984890818596, 0.05243551731109619, 0.054495517164468765, 0.06875937432050705, -0.0017289090901613235, -0.07963816821575165, -0.1031886637210846, 0.027889309450984, 0.062457893043756485, 0.11811305582523346, -0.09139144420623779, 0.10710582882165909, -0.05150076746940613, 0.05789261311292648, 0.009114831686019897, -0.043008606880903244, -0.11207932233810425, -0.02770649641752243, 0.010117214173078537, 0.11488077044487, 0.050860971212387085, -0.03132733330130577, -0.1301686316728592, 0.15008673071861267, 0.12512928247451782, 0.06884421408176422, 0.10575048625469208, 0.04740498214960098, 0.05353909730911255, -0.08430691063404083, 0.017214447259902954, -0.01516887079924345, -0.029719945043325424, -0.006383819971233606, -0.1278848797082901, 0.060917407274246216, -0.16144421696662903, -0.13438692688941956, 0.07608100771903992, -0.00330269243568182, -0.07618258148431778, 0.02285361848771572, 0.1614328771829605, -0.03492066264152527, 0.046437159180641174, -0.02649042010307312, 0.002538809785619378, 0.127235546708107, -0.005414300132542849, 0.051701221615076065, 0.04298742860555649], "changes": {"1wk": -6.272302575543676}}, {"text": "Intellia makes progress on HAE study; 2 more China drug deals BioPharma Dive \u00b7 Daniel Tadevosyan via Getty Images BioPharma Dive staff Wed, Jan 22, 2025, 1:00 PM 2 min read In This Article: NTLA -7.56% AVBP -3.43% AMLX -6.30% ATRA -4.05% ^YH206 +2.08% This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter . Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have missed. Gene editing specialist Intellia Therapeutics has dosed the first patient in a Phase 3 study of its in vivo CRISPR therapy for the rare disease hereditary angioedema, or HAE. The placebo-controlled study will test the efficacy of Intellia\u2019s drug, dubbed NTLA-2002 , in 60 adults with either Type 1 or Type 2 HAE, which can cause severe swelling attacks. The company expects to complete enrollment in the second half of this year and, pending positive results, to submit for U.S. approval in 2026. Updated follow-up data from a Phase 1/2 study will be presented this year, Intellia said Wednesday. \u2014 Delilah Alvarado ArriVent BioPharma has struck a deal with Shanghai-based Lepu Biopharma Co. to gain access to an antibody-drug conjugate for gastrointestinal cancer. ArriVent, which went public one year ago , will pay $47 million to Lepu for rights outside of China, Hong Kong, Macau and Taiwan to develop and market the ADC, dubbed MRG007. Arrivent plans to soon ask for a green light to begin clinical testing in the U.S. Lepu could receive up to $1.16 billion in additional milestone payments. \u2014 Delilah Alvarado The Food and Drug Administration has put on hold on clinical testing by Atara Biotherapeutics , including studies testing its drug Ebvallo as well as an earlier-stage CAR-T cell therapy. The hold, which halts the screening and enrollment of new patients into Atara\u2019s trials, is due to compliance issues flagged by FDA inspectors at a recent visit to a third-party manufacturing site. Those issues also led to the agency\u2019s recent rejection of Ebvallo for post-transplant lymphoproliferative disease associated with Epstein-Barr virus. Atara said it\u2019s discussed remedies with the FDA and will work \u201cexpeditiously\u201d to resolve the holds. \u2014 Ned Pagliarulo Amylyx Pharmaceuticals can move forward with a Phase 1 trial testing its experimental medicine AMX0114 for ALS after the FDA lifted a clinical hold on the study. In a statement Tuesday, Amylyx said will now work to screen, enroll and dose patients across sites in the U.S. The company, which was forced to withdraw from market an earlier ALS drug after follow-up testing showed it didn\u2019t work, plans to soon begin a Phase 1 study of AMX0114 in Canada. Early data from testing of AMX0114 could come later this year. \u2014 Ned Pagliarulo Story Continues Prolium Bioscience , a startup backed by RTW Investments , has licensed an experimental bispecific antibody from China-based developers InnoCare Pharma and KeyMed Biosciences , according to a Monday statement from the latter companies. Dubbed ICP-B02, the antibody drug binds to both CD20, a protein found on the surface of tumor cells, and CD3, an immune cell protein. Prolium will have rights to develop the drug for oncology indications in \u201cex-Asia regions\u201d and globally for indications outside of oncology. Payments to InnoCare and KeyMed could total as much as $520 million, including an unspecified upfront fee. \u2014 Ned Pagliarulo Recommended Reading The BioPharma Dive Awards for 2019 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "HAE", "date": "2025-01-22T10:00:00+00:00", "sentiment": {"score": 0.18966992385685444, "confidence": 0.20194925367832184, "probabilities": {"positive": 0.20194925367832184, "negative": 0.0122793298214674, "neutral": 0.7857714295387268}}, "embedding": [-0.1149408221244812, -0.1300571858882904, -0.044073961675167084, -0.030240550637245178, -0.026900211349129677, -0.12828290462493896, -0.04798159748315811, 0.23578111827373505, 0.0060960883274674416, 0.06001759320497513, -0.008360441774129868, 0.09284365177154541, -0.0029717590659856796, 0.017617100849747658, -0.08401821553707123, 0.05739771947264671, -0.01534108817577362, -0.08971332013607025, -0.10599863529205322, 0.07929007709026337, -0.044210366904735565, 0.004618214443325996, 0.08487949520349503, 0.03262817859649658, -0.10888731479644775, -0.012263382785022259, 0.021556684747338295, -0.010724509134888649, -0.14850011467933655, -0.07387170195579529, 0.0424305684864521, 0.11098192632198334, -0.0049224188551306725, -0.08111999183893204, 0.059932246804237366, -0.0669194757938385, -0.0703706368803978, 0.015833191573619843, -0.05022890865802765, -0.0440981425344944, 0.06197008490562439, -0.17638826370239258, -0.10722878575325012, 0.030978510156273842, 0.05990485101938248, -0.14267419278621674, -0.04453003779053688, -0.03938382863998413, -0.00842294842004776, 0.15170389413833618, -0.21536016464233398, -0.14652085304260254, -0.009614083915948868, 0.03748951107263565, -0.06335730105638504, -0.04254652559757233, -0.06732168793678284, -0.08170114457607269, 0.032240793108940125, 0.038579825311899185, -0.03493914008140564, -0.06644582748413086, 0.018964899703860283, -0.02397812530398369, -0.005381687544286251, 0.02876303717494011, 0.09138979017734528, -0.15908309817314148, 0.06496399641036987, -0.07284007966518402, 0.10202253609895706, -0.06412854790687561, -0.026733221486210823, 0.21606338024139404, -0.06407564878463745, 0.056043822318315506, 0.14297319948673248, 0.09803200513124466, 0.22764724493026733, -0.13888145983219147, 0.11220788210630417, -0.01325897965580225, 0.14545410871505737, -0.006885077804327011, 0.011848807334899902, 0.07306713610887527, 0.001532409805804491, 0.161471426486969, 0.07489408552646637, -0.008246882818639278, 0.17288196086883545, 0.02607034333050251, -0.04193607717752457, -0.01680123805999756, 0.06025787815451622, -0.07363708317279816, 0.010593891143798828, 0.0051625631749629974, 0.0018349690362811089, 0.008939883671700954, 0.025729041546583176, 0.04345524311065674, -0.1623641401529312, -0.07202307879924774, -0.0537107028067112, -0.05037525296211243, 0.06552132964134216, -0.1101560965180397, 0.06449219584465027, 0.02353082038462162, -0.10266493260860443, 0.031547270715236664, 0.014801638200879097, -0.024419624358415604, -0.12707962095737457, 0.22467097640037537, -0.02222236804664135, 0.036234740167856216, 0.11832989752292633, -0.052643999457359314, 0.02675689198076725, -0.04313090443611145, 0.009772388264536858, -0.08087444305419922, 0.23399843275547028, 0.04199456050992012, -0.21769486367702484, 1.3264175398922995e-32, 0.03633871674537659, 0.07516153901815414, -0.03160090744495392, 0.012341653928160667, -0.07493717968463898, -0.02815525233745575, 0.06417932361364365, -0.03193606436252594, -0.14030538499355316, -0.10276608914136887, -0.1563146710395813, -0.08060470968484879, -0.017274662852287292, 0.0859617218375206, -0.0677136778831482, -0.057386189699172974, -0.05509005859494209, 0.03351772949099541, -0.14528627693653107, 0.028584342449903488, 0.08636397123336792, -0.02548465132713318, -0.008504785597324371, -0.05118994414806366, -0.09360317885875702, 0.10162443667650223, -0.09730641543865204, 0.06763029843568802, 0.16883227229118347, 0.06594957411289215, -0.14712300896644592, -0.048015058040618896, 0.07479780912399292, -0.032784659415483475, -0.03984729200601578, -0.00521416962146759, -0.03835824504494667, -0.08227911591529846, -0.035357557237148285, 0.16009414196014404, 0.03236031532287598, 0.21410852670669556, -0.09343424439430237, -0.09942208230495453, 0.11140510439872742, -0.08725705742835999, -0.10399674624204636, 0.025477172806859016, 0.00966440699994564, -0.02479584887623787, -0.047638941556215286, -0.03619762137532234, 0.007497699931263924, -0.06335018575191498, -0.004076237790286541, 0.03325045481324196, -0.14156444370746613, -0.0509323813021183, 0.17879298329353333, 0.0880538672208786, 0.05359834060072899, 0.0976819097995758, -0.005914777517318726, 0.11097787320613861, -0.04572509601712227, 0.10188515484333038, -0.071710966527462, -0.06901702284812927, -0.07014220952987671, 0.11806836724281311, 0.049942467361688614, -0.09414586424827576, 0.07060901075601578, 0.010643227025866508, -0.07317556440830231, -0.11374367028474808, 0.014790251851081848, 0.13736051321029663, 0.03102611005306244, -0.030196692794561386, 0.12164192646741867, -0.012618880718946457, 0.023778386414051056, 0.13024285435676575, -0.012475836090743542, -0.09399210661649704, -0.016571994870901108, 0.006599382497370243, -0.19787056744098663, -0.057149361819028854, 0.1303594410419464, -0.044643279165029526, -0.0075151314958930016, -0.024810995906591415, -0.019506461918354034, -1.249618085849264e-32, -0.08077376335859299, -0.026231594383716583, -0.1006585955619812, -0.02101762406527996, -0.009291643276810646, 0.14085450768470764, 0.08761955797672272, -0.03382241725921631, 0.20001007616519928, -0.07772810757160187, 0.08910711109638214, 0.048007939010858536, 0.0200029443949461, -0.08531614392995834, -0.04728345945477486, 0.025225605815649033, -0.01654847525060177, -0.09969034790992737, -0.03173115849494934, 0.07224210351705551, -0.0012921574525535107, 0.09458516538143158, -0.057787105441093445, 0.05704508349299431, 0.006726023741066456, 0.0672091692686081, 0.06408827006816864, 0.08191905915737152, 0.032747820019721985, -0.06346789747476578, -0.0755135789513588, 0.03356079012155533, -0.23764710128307343, 0.0040749963372945786, 0.009202820248901844, -0.06629740446805954, 0.05804891139268875, -0.09084439277648926, -0.021359335631132126, -0.0628688707947731, 0.0684521347284317, 0.007205698173493147, -0.024651115760207176, 0.08395304530858994, 0.02425411157310009, 0.07881786674261093, 0.02953488938510418, -0.007843287661671638, 0.12486082315444946, -0.029208485037088394, -0.02029607445001602, 0.0036164692137390375, 0.05363108590245247, 0.03233177214860916, -0.055100083351135254, -0.039781663566827774, 0.10138169676065445, -0.05419031158089638, -0.13859474658966064, 0.03034648671746254, -0.014773705042898655, 0.06504657864570618, 0.014275024645030499, -0.0021056989207863808, 0.07607629150152206, 0.18322217464447021, 0.08954284340143204, 0.02213180810213089, 0.01846085488796234, -0.16414545476436615, -0.062329668551683426, -0.07967305183410645, -0.01619657874107361, -0.10110919177532196, 0.10317246615886688, 0.10601553320884705, -0.09983550012111664, -0.05126369372010231, -0.04413212463259697, -0.0012557529844343662, 0.013423621654510498, -0.10974393784999847, 0.004509593825787306, -0.05218036472797394, 0.042057305574417114, 0.05493088811635971, -0.022019172087311745, 0.0066374423913657665, -0.0038278724532574415, -0.030223466455936432, -0.0989692211151123, -0.12043459713459015, -0.07772135734558105, 0.06166104972362518, -0.044994138181209564, -1.0073826217649184e-07, 0.1688099503517151, -0.12774339318275452, 0.0016295209061354399, -0.05685678869485855, -0.04933962970972061, -0.06684006005525589, -0.08031092584133148, 0.06845973432064056, 0.019569391384720802, 0.12891551852226257, 0.026337984949350357, 0.1950799524784088, -0.07079611718654633, -0.03529039025306702, -0.01921221800148487, 0.03241521120071411, 0.025447189807891846, 0.06468226760625839, -0.08233701437711716, -0.002282814122736454, -0.07138488441705704, 0.03678862005472183, 0.08514776825904846, -0.11641102284193039, 0.1477367877960205, -0.010266202501952648, -0.042219072580337524, 0.014804084785282612, -0.03519578278064728, -0.08158977329730988, -0.04852595925331116, -0.060175858438014984, 0.12477689236402512, 0.09076496958732605, -0.035501159727573395, -0.16981685161590576, 0.11865270137786865, 0.07940605282783508, 0.09329238533973694, 0.09500505775213242, 0.06964614242315292, 0.017746571451425552, -0.0324801504611969, -0.01353377103805542, 0.023337215185165405, -0.03333752602338791, -0.02524668537080288, -0.08665970712900162, 0.12665463984012604, -0.05929339677095413, -0.07150933891534805, 0.023094674572348595, 0.024678267538547516, -0.07051031291484833, 0.019012942910194397, 0.14426204562187195, -0.05407300591468811, -0.05915912613272667, 0.027327097952365875, -0.009957225061953068, 0.1369960904121399, -0.08624600619077682, 0.14744047820568085, 0.0831252783536911], "changes": {"1wk": -6.0804351428121794}}]